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Probiotics can influence intestinal responses and mucosal immunity 
either directly or indirectly through transient modulation of the 
endogenous microenvironment or the immune system.  During space 
travel, astronauts experience various physiological stresses including 
putting them at risk for infections or inappropriate immune responses.  
Macrophages and monocytes are a key cell type involved in innate 
immunity.  The effects of dairy milk or soy milk base fermented with           
S. thermophilus ST5 in combination with either B. longum R0175 or             
L. helveticus R0052 on the cell line U937 and all-trans retinoic acid 
differentiated U937 were examined under normal gravity and simulated 
microgravity conditions, in order to screen for effects on monocytes and 
macrophages.  Soy and milk ferments demonstrated the ability to modulate 
certain aspects of the innate immune system, both in normal gravity and in 
simulated microgravity.  These probiotics affected U937 cells differently 
depending on differentiation stage (monocyte or macrophage) and whether 
or not the cells were tested in regular gravity or in simulated microgravity 
conditions.  These results provide insight into effects on this aspect of 
innate immunity and may provide guidelines to potential in vivo 
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Probiotics and the Immune System 
Probiotics are non-pathogenic, living microorganisms (bacteria or, less 
commonly, yeasts) that impart a health benefit to the host when ingested, 
particularly when present in the gastrointestinal tract and vagina (Douglas and 
Sanders, 2008; Pham et al, 2008; Elmer, 2001; Madsen, 2001; Marteau et al, 
2001). They are often referred to as “living drugs”.  In a definition by the Food 
and Agricultural Organization and the World Health Organization, probiotics are 
live microorganisms which, when administered in adequate amounts, confer a 
health benefit on the host.  However, there is some discussion as to whether or 
not the bacteria must be viable to be beneficial and to be classified as a probiotic 
(Ostad et al, 2009; Kataria et al, 2009; Douglas and Sanders, 2008; Lopez et al, 
2008; Simakachorn et al, 2000).  Probiotics can influence intestinal physiology 
either directly or indirectly through transient modulation of the endogenous 
microenvironment or the immune system (Ng et al, 2010; Sanz and De Palma, 
2009; Drakes et al, 2004; Marteau et al, 2001).  Clinical studies suggest that 
probiotics might be useful in stimulation of the immune system, prevention of 
allergic diseases, control of gastrointestinal tract inflammatory diseases and 
potentially cancer prevention (Trafalska and Grzybowska, 2004). Numerous 
probiotic microorganisms (e.g. Lactobacillus rhamnosus GG, L. reuteri, 
bifidobacteria spp. and certain strains of L. casei or the L. acidophilus group) are 
used in probiotic or “functional” foods, particularly fermented milk products, or 
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have been investigated with regard to their medicinal use (de Vrese  and 
Schrezenmeir, 2008).  Probiotic microbial species such as those listed above 
may act by changing the composition of the gut microbiota (Trafalska and 
Grzybowska, 2004), although their fate in the gastrointestinal tract (GI tract) and 
overall effects differ among strains, with colonization often being transient 
(Douglas and Sanders, 2008; Marteau et al, 1993).  The protective effects of 
probiotics against infections in the intestine have been shown in animal models 
(Corthier, 1997; Gibson et al, 1997; Elmer et al, 1996) and humans (Barbara et 
al, 2008; Vanderpool et al, 2008; Hickson et al, 2007) but the possible modes of 
actions vary, including production of short chain fatty acids (SCFA), hydrogen 
peroxide, or other antimicrobial substances, competition for nutrients or adhesion 
receptors, antitoxin actions, and stimulation of the immune system through direct 
interactions or cellular and metabolic products (Lebeer et al, 2010; Neish, 2004; 
Marteau et al, 2001).  SCFA and their salts such as acetate, butyrate and lactate 
have recently been implicated in effects on nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB; a transcription factor for stress signals) 
expression induced by lactic acid bacteria (Kumar et al, 2009).  In the gut, SCFA 
reach millimolar concentrations which are absorbed through passive and active 
transport (Tedelind et al, 2007) and are commonly associated with anti-
inflammatory activity (Maslowski et al, 2009; Tedelind et al, 2007; Andoh et al, 
1999).  
 The mucosal surfaces of the GI tract, reproductive tract and respiratory 
tract are in direct contact with the external environment and are therefore 
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susceptible to invasion by pathogens.  The GI tract plays two roles in human 
physiology: digestion and uptake of nutrients, and the more daunting task of 
protecting the body from potentially harmful microbes, while inducing tolerogenic 
responses to innocuous food, commensals and self-antigens (Mason et al, 
2008).  A fairly large overall surface area allows the gut to house the largest 
number of immune cells in the body, in gut-associated lymphoid tissue (GALT) 
locations including Peyer’s Patches (PPs) and mesenteric lymph nodes (MLNs).   
Key cell types participating in mucosal immunity include not only T and B 
lymphocytes, but also dendritic cells (DC), macrophages and intestinal epithelial 
cells (IECs), which are key players in innate immunity (See Appendix A) (Mason 
et al, 2008; Garside et al, 2004).  Cell types involved in innate immunity have the 
ability to discriminate between harmful pathogens and the harmless members of 
the commensal flora by using cell surface Pattern Recognition Receptors (PRRs) 
such as the toll-like receptors (TLRs) (Albiger et al, 2007; Harris et al, 2006; Kelly 
and Conway, 2005).   
 Commensal microflora, or, normal indigenous microbiota, consists of 
those microorganisms which are present on body surfaces covered by epithelial 
cells and are exposed to the external environment (Tlaskalová-Hogenová et al, 
2004).  The presence of the commensal microbiota helps keeps pathogenic 
bacteria in check by out-competing those pathogens.  At the interface between 
the contents of the gut and host tissues, the intestinal epithelium must 
incorporate pro- and anti-inflammatory signals to regulate immune responses 
(Clavel and Haller, 2007).  An abnormal host response to the normal intestinal 
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microbiota can lead to chronic intestinal inflammation. Probiotic bacteria may 
moderate the intestinal microflora and the mucosal immune response and can be 
an effective therapy for such diseases as Irritable Bowel Syndrome (IBS), and 
potentially for ulcerative colitis and Crohn's disease (Heller and Duchmann, 
2003).  Regulation of commensal microbiota composition by probiotics also offers 
the possibility to influence the development of mucosal and systemic immunity 
(Tlaskalová-Hogenová et al, 2004).   
 One of the most complex systems in vertebrate species is that of the 
immune system.  There is a need for an organism to detect material foreign from 
its own tissues.  The immune system acts though a set of biological processes 
that protect an organism against disease by detecting and killing pathogens and 
tumour cells.  There are two branches of the immune system in vertebrates: 
innate immunity and adaptive immunity.  Innate immunity defends the host in a 
rapid and non-specific manner but confers no lasting protection (Alberts et al, 
2002) and usually has common mechanistic elements.  For example, a bacterial 
infection might set off a response of biochemical pathways that might also be 
utilized by other types of tissue damage that entail an immediate response, such 
as a skin burn (Ishii et al, 2008).  The adaptive immune system is activated by 
the innate immune system (Janeway et al, 2001) and provides the host with the 
ability to remember and recognize individual pathogens and mount stronger 
attacks in subsequent exposures (Pancer and Cooper, 2006).  
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Monocytes, macrophages and IECs are among the participants at the 
frontline of the innate immune system.  IECs provide a physical and 
immunological interface against microbes that pass through the intestinal lumen 
while monocytes and macrophages phagocytose cellular debris and pathogens 
and digest the pathogen with enzymes and toxic products of the oxidative burst 
reaction.  Monocytes, macrophages and IECs produce cytokines upon 
intracellular infection with pathogenic bacteria (Lucas and Greaves, 2001; 
Kagnoff and Eckmann, 1997; Jung et al, 1995; Eckmann et al, 1993).  
Macrophages also function as antigen presenting cells (APCs) and are part of 
both the adaptive and innate immune systems (Thomson and Robbins, 2008).  
Instead of directly annihilating invading pathogens, APCs degrade pathogen 
proteins and, as their name suggests, present the fragments at their cell surface 
using Major Histocompatibility Complex (MHC) molecules.  These fragments 
displayed by the APCs are recognized by helper T cells and cytotoxic T cells, 
leading to their activation through costimulatory molecule-dependent process.    
T cell activation in turn provides help for activated B cells, thus initiating antibody 
production and an immune response against the pathogen. 
 Two common pyrogens (a substance that induces fever and pro-
inflammatory immune response) used in immunology research are Tumour 
Necrosis Factor Alpha (TNF-α; also a pro-inflammatory cytokine) and 
Lipopolysaccharide (LPS).  TNF-α is manufactured by macrophages to induce 
apoptotic cell death and induce inflammation, and to prevent tumourigenesis and 
viral replication via cell lysis.  TNF-α receptors (TNF-R) are associated with pro-
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caspases through adapter proteins such as FAS-Associated protein with Death 
Domain (FADD) and TNFRSF1A-Associated via Death Domain (TRADD) that 
cleaves other inactive pro-caspases and trigger the caspase cascade, 
committing the cell to apoptosis.  LPS is an endotoxin and a component of the 
outer-membrane of Gram-negative bacteria, and stimulates an immune response 
through a CD14/TLR4/MyD88/NF-κB pathway.  LPS also induces TNF-α 
production by macrophages (Alciato et al, 2010; Allon et al, 2010; Tumurkhuu et 
al, 2009).  Both TNF-α and LPS are often used in cell culture as a challenge to 
induce pro-inflammatory responses in target cells (Raabe et al, 1998; Drouet et 
al, 1991).  Each toxin or challenge can act in a different way on individual cell 
lines.  Both LPS and TNF-α have been utilized to challenge the human 
macrophage cell lines THP-1 and U937 (Mezayen et al, 2007; Steube et al, 
2000; Vlahopoulos et al, 1999; Neale et al, 1988) 
The outcome of these challenges on cells is, as stated previously, an 
innate response which includes production of certain key cytokines.  Cytokines 
are a class of signaling molecule used by the body in cellular communication and 
are important immunomodulating agents.  Many cytokines can be divided into 
two general categories: pro-inflammatory (including IL-8 and TNF-α) and anti-
inflammatory (including IL-10 and TGF-β1).  IL-8 is widely used as a gauge of 
inflammatory action in laboratory practice because it is one of the major 
mediators of the inflammatory response in the body (Vlahopoulos et al, 1999).  
TNF-α, in addition to being used as a challenge for cell lines, is itself a cytokine 
that through the TRADD pathway intensifies activation of NF-κB, increasing the 
7 
 
inflammatory response.  Both are considered positive acute phase proteins 
where their plasma concentrations increase in response to inflammation.  IL-10, 
on the other hand, blocks NF-κB activity and is involved in the regulation of the   
JAK-STAT (Janus Kinases and Signal Transducers and Activators of 
Transcription) pathway (Moore et al, 2001).  Additionally, knockout studies in 
mice have shown that IL-10 is an essential immunoregulator in the intestinal tract 
(Ina et al, 2005).  TGF-β1 is a regulatory cytokine with effects that vary 
depending on location or situation; TGF-β1 promotes regulatory T-cell 
development, down-regulates pro-inflammatory cytokine production and also acts 
as a class switching factor, promoting IgA production (Ouyang et al, 2010; Ghio 
et al, 2009; Watanabe et al, 2001).  It is important to look at both pro- and anti-
inflammatory responses to fully understand the range of immunomodulatory 
activity to a particular stimulant or product. 
 Fermented milk and soy products containing probiotics have recently 
become a “hot topic” among immunologists and gastroenterologists (Rekha and 
Vijayalakshmi, 2008; Farnworth et al, 2007; Saikali et al, 2004; Heller, 2001), and 
is a focus of research and product development for industry.  However, probiotics 
are not a novel discovery.  At the beginning of the 20th century, Russian Nobel 
laureate and Pasteur Institute professor Eli Metchnikoff first suggested that it is 
possible to modify the gut flora and replace harmful microbes with useful ones 
(Metchnikoff, 1907).  Later, some strains of L. acidophilus were determined to be 
active when introduced into the human digestive tract (Rettger et al, 1935). In 
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1965, Lilly and Stillwell first coined the term “probiotic” (Lilly and Stillwell, 1965) 
meaning, “for life”.   
The probiotic cultures themselves are believed to impart the majority of 
health benefits in fermented cow’s milk and soy products.  Aside from providing 
the host gut with beneficial bacteria and increasing intestinal mobility (Seki et al, 
1978) and potentially increasing vitamin content (Alm, 1982; Shahani and 
Chandan, 1979), the lactic acid bacteria (LAB) also secrete a variety of 
antimicrobial metabolites, compete for nutrients and adhesion sites in the gut 
against pathogenic bacteria (Sanz et al, 2007) and may provide 
immunomodulatory effects, among a list of other possible activities (Heyman, 
2000).  Today, lactobacilli and bifidobacteria (also known as LAB) are the primary 
probiotics used in fermented soy and dairy foods such as yogurt and dietary 
supplements (Cogan et al, 2007), and common starter cultures include 
Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus 
(Farnworth et al, 2007).  The probiotic cultures generally do not grow rapidly in 
cow’s milk, and in yogurt manufacture, do not reach as high numbers as starter 
cultures achieve (Wagar et al, 2009; Champagne et al, 2005).  Some studies 
have previously shown that soy is a good substrate for the growth of probiotic 
bacteria (Champagne et al, 2009; Scalabrini et al, 1998; Mital et al, 1974; 
Angeles and Marth, 1971) but not for that of the starter culture L. delbrueckii 
subsp. bulgaricus (Wang et al, 2002; Karleskind et al, 1991; Mital et al, 1974).   
S. thermophilus on the other hand, has been shown to grow well in both cow’s 
milk and soy substrate (Champagne et al, 2009; Farnworth et al, 2007; Wang et 
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al, 2006; Hsieh and Chou, 2006).  S. thermophilus has also previously been 
shown to stimulate innate immunity in mice models (Perdigon et al, 1995). 
Bovine Milk, Soy Milk and the Human Immune System 
Bovine milk and milk products, while containing a number of essential 
nutrients, have seen a decrease in consumption following claims of negative 
health effects (Haug et al, 2007; Insel et al, 2004).  This critique arises especially 
since milk fats contain a large percentage (more than half) (Jensen and 
Newburg, 1995) of saturated fat, which has become associated with obesity, 
weight gain and heart disease.  However, the common misconception that bovine 
milk causes an increase in mucus production and respiratory symptoms has 
never actually been confirmed (Wüthrich et al, 2005; Pinnock et al, 1990). 
Aside from macronutrients, bovine milk contains a large number of 
biologically active components such as hormones, immunoglobulins (Ig), growth 
factors, enzymes and other peptides.  Insulin-like Growth Factor (IGF) and 
Epidermal Growth Factor (EGF) regulate cell growth and development especially 
in the milk glands of lactating ruminants such as cows and sheep (Herbst, 2004; 
Forsyth 1996; Glimm et al, 1992), and the GI tract of bovine and ovine neonates 
(Blum and Baumrucker, 2008; Blum and Baumrucker, 2002; Odle et al, 1996).  
There may also be a human connection with these developmental changes 
(Purup et al, 2006; Gill et al, 2000).  As bovine milk and its bioactive components 
are ingested, they survive the digestion process (Koldovsky, 1989), and affect 
the regions of the GI tract differently (Blum and Baumrucker, 2008).  In addition, 
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IgG, IgA and IgM (Korhonen et al, 2000), hormones and hormone-like peptides 
are also potential factors found in bovine milk that are capable of modulating the 
immune system at the GI tract level (Clare and Swaisgood, 2000).  However, 
bovine milk is a very complex solution and there may be components that have 
yet to be characterized.   
Soy milk, on the other hand, is often touted as a healthy alternative to 
dairy milk, especially for those who are lactose intolerant or following a 
vegetarian or vegan diet. Soy milk has several advantages over dairy milk in 
terms of nutrition.  Ounce for ounce, soy milk has less calories and fat than dairy 
milk, contains fiber, contains potentially bioactive molecules such as phenolic 
acids, saponins, isoflavones and phytosterols, lacks casein (an important aspect 
for those with milk allergies) and is a source of vitamin E and lecithin (USDA 
Nutrient Data Laboratory, 2010; Ishimi, 2009; Xu and Chang, 2009; Bolling and 
Parkin, 2008; Sakai and Kogiso 2008).  A diet that includes soy-based products 
has been shown to modulate some aspects of the immune system (Maskarinec 
et al, 2009; Matsushita et al, 2008; Ryan-Borchers et al, 2006), possibly due to 
its isoflavone content.  Soy milk fermentation has also been reported to improve 
soy isoflavone bioavailability (Tsangalis et al, 2005; reviewed in Uzzan and 




Issues with Space Travel and Immunity 
Experience with space exploration to date has raised more questions 
regarding nutritional requirements for astronauts than it has answered.  As 
mission lengths continue to increase, nutrient imbalances due to alterations in 
food intake, dietary requirements, bioavailability, or excretion, may become more 
important (Seddon et al, 1994).  Among the many physiological problems 
astronauts experience while in zero gravity are increase in stress, increased 
metabolic rate and increase in protein turnover.  Changes in activity of the 
immune system have also been reported including reduced phagocytic and 
oxidative burst activity of monocytes (Kaur et al, 2005).  It has also been shown 
that there is an increase in circulating IL-1, a pro-inflammatory cytokine and 
endogenous pyrogen (Huntoon et al, 1994; Stein et al, 1993; Leach et al, 1988; 
Leach et al, 1983).  Decreases in lymphocyte blastogenesis, cytokine production, 
and natural killer cell activity have also been reported after space flight 
(Sonnenfeld, 1999).  These changes start to occur after only a few days of space 
flight, and some changes continue throughout long-term space flight 
(Sonnenfeld, 1998) or even after cessation of microgravity conditions (Ritz et al, 
2005).  T cell activation is decreased and a detectable Th2 cytokine shift also 
appears during and after spaceflight (Crucian et al, 2008).  It is known that 
exposure of T cells in culture to actual or modeled low gravity is often 
accompanied by a major inhibitory effect, remarkably reducing their mitogenic 
activation process and inhibiting further signaling pathways such as the NF-κB 
and MAPK pathways (Boonyaratanakornkit et al, 2005; Cogoli et al, 1984). 
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 Modeled microgravity has been reported to have varied effects including 
severely altered growth rate, gene expression, cytoskeletal structures, motility, 
and perhaps most importantly, cytokine production in cell culture (Cogoli-Greuter 
et al, 2004; Lewis, 2002; Cogoli, 1997; Cogoli and Cogoli-Greuter 1997; Cogoli, 
1993).  The cell cycle itself is influenced by gravity; during a 14-day space flight, 
an accumulation of p53 has been found in epidermis (keratinocytes) and muscle 
(myocytes), indicating that central regulatory molecules of nuclear signal 
transduction and cell cycle are influenced by gravity (Ohnishi et al, 1999).  Meloni 
et al. (2006) has recently shown that simulated microgravity leads to substantial 
changes in the cytoskeleton of monocytes.  This in turn influences motility, and 
as revealed during an International Space Station (ISS) experiment, a severe 
reduction in the locomotion ability of monocytic cells in microgravity (Meloni et al, 
2008) possibly due to changes in cell-cell adhesion.  However, little research has 
been completed on macrophage stage cells in actual or modeled microgravity. 
The migration of immune cells is a crucial process during many 
physiological and pathophysiological conditions such as development, defense 
against infections and wound healing (Horwitz and Parsons, 1999; Lauffenburger 
and Horwitz, 1996). Leukocytes move through the body in order to keep the 
organism under immunological surveillance and to respond to pathogenic 
invading microorganisms, and microgravity may affect this motility (Li et al, 2009; 
Meloni et al, 2006; Buravkova and Romanov, 2001).  Again, this is perhaps due 
to changes in the cytoskeleton (Crawford-Young, 2006; Meloni et al, 2006; 
Hughes-Fulford, 2003).  However, this has received little attention.  But it seems 
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that not all immune system cells are equally affected by the absence of “gravity”.  
Studies with natural killer cells in simulated weightlessness and in actual 
microgravity revealed that neither cytotoxic effects nor interferon production is 
altered in microgravity (Buravkova et al, 2004), although others have reported a 
decreased concentration of natural killer cells (Sonnenfeld and Shearer, 2002; 
Levine and Greenleaf, 1998). 
In addition to direct effects, the intestinal microflora of the astronauts may 
also be affected, although there is little published. As early as two weeks into the 
confinement imposed by space flight, there is a significant reduction in the 
number of bacterial species that can be isolated from the intestinal tract as well 
as an interchange of intestinal bacteria between crew (Hales et al, 2002).  Such 
large shifts in the composition of the commensal microflora may also provide 
opportunities for the dissemination and spread of antibiotic resistance genes. 
These effects might be circumvented, or at least ameliorated, by regular intake of 
probiotic foods (Taylor and Sommer, 2005).   
The RCCS™ and Simulated Microgravity 
Because actual microgravity is clearly difficult and expensive to work in, 
modeled microgravity conditions must be substituted on the ground.  The term 
“microgravity” (or “zero gravity”) is actually somewhat of a misnomer. The 
weightlessness felt while in orbit around the earth in a shuttle or space station is 
not the result of the force of gravity being eliminated or even significantly reduced 
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(zero gravitational acceleration).  Instead, it is that of the object or person 
essentially freefalling, falling out of the orbit and then returning to orbit by 
centripetal force, without colliding or experiencing any other forces.  The 
difference between true freefall and the freefall of “zero gravity” is that 
gravitational acceleration causes a net change in the direction (around the earth), 
rather than the magnitude (falling faster).   
Recently, a new cell culture technology has been developed by the 
National Aeronautics and Space Administration (NASA), and manufactured by 
Synthecon Incorporated (Houston, Texas) to study the effects of microgravity on 
cells.  The Rotary Cell Culture System™ (RCCS) (Unsworth and Lelkes, 1998; 
Schwarz and Wolf, 1991), also called a bioreactor or rotating wall vessel (RWV), 
is a disk or drum shaped chamber which rotates along a horizontal axis, filled 
completely with cell culture medium (bubble free), allowing the cells to develop in 
an environment similar to the freefall of microgravity (See Appendix B).  Cells are 
maintained in a gentle fluid orbit that creates a sustained low-shear force (less 
than 1 dyne/cm2)†
                                                             
† 1 dyne = 10 µN, where 1 N = 1  
, low-turbulence environment for cell growth (Hammond and 
Hammond, 2001).  This design allows a constant rotation normal to the 
gravitational field, resulting in a culture condition in which the gravitational 
vectors are randomized over the surface of the cells (Klaus, 2001).  Oxygen and 
carbon dioxide are allowed to reach the cells though a flat silicone rubber gas 
transfer membrane wall in the chamber.  This innovation has allowed 
researchers to study the effects of microgravity on cells without entering 
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microgravity themselves (Chen et al, 2007; Clement et al, 2007; Saxena et al, 
2007; Wang et al, 2005). 
 The fluid mechanics affecting objects in a bioreactor have been studied in 
great detail (Hammond and Hammond, 2001; Klaus, 2001; Klaus et al, 1998; 
Gao et al, 1997; Wolf and Schwarz, 1991).  The cells are in a state of constant 
freefall because of hydrodynamic forces counteracting the gravitational 
sedimentation in the bioreactor.  Turbulence and shear forces are minimized by 
the solid-body rotation of the cell culture media, as indicated by Stokes’ Law ‡
                                                             
‡  where  is friction (in N),  is fluid viscosity (in Pa·s), R is the 
radius of the spherical particle (in m) and V is the particles velocity (in m/s) 
 for 
flow around spherical objects (Hammond and Hammond, 2001; Gao et al, 1997; 
Tsao et al, 1994).  Assuming that a cell acts similarly to the spherical particle 
mentioned in Stokes’ Law, their microscopic size and relative low density 
suggests minimal shear force.  
 There are two different types of vessels the RCCS™ base accepts: the 
High Aspect Ratio Vessel (HARV) and the Slow Turning Lateral Vessel (STLV).  
The STLV comes in 55 to 500 mL sizes, are drum shaped, and are best used for 
batch cultures of adherent cells (See Appendix C).  The HARV, available in 10 
mL and 50 mL sizes, are disk shaped and come in both in a reusable, 
autoclavable version, and a disposable, pre-sterilized version (See Appendix D).  
The vessels used in this research were disposable 10 mL HARVs.  Table 1 
shows selected literature using the HARV to simulate microgravity. 
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Cell Culture Approaches 
 The most common system for modeling the immune system in the field of 
probiotics and immunological research are in vitro cell culture and in situ animal 
studies.  Although relatively simple, cell lines provide a “first look” in evaluating 
effects of a growth factor, antigen or other stimulant before moving on to in situ 
models.  The early stages of cell culture began in the 1900’s and have since then 
presented the basis for hybridomas and monoclonal antibody production, two 
significant events in biotechnology history.  In cell culture, standardized cell lines 
are established from a sample taken from transformed tissue.  Because of the 
deregulation of the cell cycle, cell lines are easily cultured and can be 
permanently maintained.   
The U937 monocytic cell line was established in 1974 and isolated from a 
37 year old male patient with hematological malignancy (Sundstrom and Nilsson, 
1976).  This cell line can be further differentiated into a more mature macrophage 
stage using phorbol 12-myristate 13-acetate (PMA), all-trans retinoic acid (ATRA) 
or 1,25-dihydroxyvitamin D3 (vitamin D3; Kulseth et al, 1998; Kitamura et al, 
2004).  The THP-1 cell line is also monocytic, but is derived from a one year old 
male patient with acute monocytic leukemia (Tsuchiya et al, 1980).  This cell line 
was established in 1980. 
 Many of the biomarkers presently used in immunological research have 
several roles which are often dissimilar between different tissues and cell types.  
The best example of this is TNF-α.  In the context of this research, TNF-α acts as 
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a challenge and an inducer of NF-κB activation and cytokine production.  
Originally, TNF-α was discovered as possessing potent tumour cytotoxicity in 
earlier animal models (reviewed in Bradley, 2008).  While typically a pro-
inflammatory stimulus, the effects of TNF-α may vary on cells at different stages 
of differentiation.  As mentioned previously, TNF-α is able to activate the         
NF-κB/TRADD and mitogen-activated protein kinase (MAPK) pathways and 
induce apoptosis through caspase activation and is commonly used to challenge 
cells in culture in order to induce an inflammatory response.  TNF-α is an 
effective inducer of IL-8 production by the U937 cell line (Vlahopoulos et al, 
1999). 
 Roswell Park Memorial Institute 1640 (RPMI 1640) cell culture media has 
been used to culture neoplastic and normal human leukocytes and was first 
developed by Moore et al (1967).  It utilizes a bicarbonate buffering system to 
resist changes in pH to maintain optimal growth conditions for the cells.         
RPMI 1640 is often supplemented with serum (Bovine serum albumin (BSA), 
fetal bovine serum (FBS) etc) and phenol red (a pH indicator). 
Immunological Cellular Outputs 
The innate immune system defends the host in a rapid and non-specific 
manner but confers no lasting protection and usually has common mechanistic 
elements. Such elements include cytokine production, growth factor production 
and cell surface protein expression, and recognition of pathogens though PRRs 
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such as TLRs and nucleotide-binding oligomerization domain-like receptors 
(NLRs).  Interleukins are a group of cytokines that were first seen to be produced 
by leukocytes (hence the name), although now it is known that they are 
expressed in a wide variety of cells (Smith and Humphries, 2009; Trevino et al, 
2005; Sharma et al, 2000).  Growth factors such as TGF-β1 are substances 
which are capable of altering cell growth and proliferation (Cheng et al, 2004; 
Matsuyama et al, 2003; Morrell et al, 2001), and also can be considered 
cytokines. 
An important cytokine is Interleukin 8 (IL-8), one of the major players of 
inflammatory response in the innate immune system (Vlahopoulos et al, 1999). It 
is also known as CXCL8, and is often measured as an indicator of a pro-
inflammatory response.  The gene for the IL-8 protein (IL8) is found in 
chromosome 4 (Modi et al, 1990), and the protein is a dimer, each monomer 72 
amino acids in length.   The main function of IL-8 is to attract target cells such as 
neutrophil granulocytes to the site of infection via chemotaxis (DiVietro et al, 
2001; Lane et al, 2001).  These neutrophils phagocytose pathogens and can also 
be activated though TLRs and NLRs, promoting their phagocytic and respiratory 
burst activity (Clarke et al, 2010).  As such, it can be said that IL-8 is the first 
domino to fall in a pro-inflammatory host response cascade. 
Another important cytokine is Interleukin 10 (IL-10), which has pleiotropic 
effects in the immune system and is considered a key immunoregulatory 
cytokine.  The gene IL10 is found in chromosome 1 (Eskdale et al, 1997), and 
the protein itself is a homodimer, each subunit consisting of 178 amino acids 
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(Zdanov et al, 1995).  IL-10 can down-regulate the expression of co-stimulatory 
molecules and MHC class II antigens and some cytokines such as Interferon 
gamma (IFN-γ) (Moore et al, 2001; Mosmann and Moore, 1991).  In addition,     
IL-10 can improve B cell survival and block NF-κB activation induced by TNF-α or 
LPS (Dhingra et al, 2009; Park-min et al, 2009; Dagvadorj et al, 2008; Nachtwey 
and Spencer, 2008) as well as induce phagocytosis of apoptotic cells and 
bacteria in monocytes (Lingnau et al, 2007; Ogden et al, 2005). 
Transforming Growth Factor beta 1 (TGF-β1) can influence cell 
proliferation and differentiation, as well as other functions depending on cell type, 
and is also considered an immunoregulatory cytokine.  The TGFB1 gene is found 
on chromosome 19 (Ghadami et al, 2000) and the protein is expressed as a 390 
amino acid precursor protein which is proteolytically processed to produce a 
mature peptide of 112 amino acids (Derynck et al, 1985).  Many cells produce 
TGF-β1 and have receptors for the protein, including immune system cells 
(Letterio and Roberts, 1998).  In monocytes and macrophages, TGF-β1 has 
mainly suppressive effects; it can inhibit proliferation and prevent the formation of 
superoxide anions (O2-) and nitric oxide (NO) intermediates (Langermans et al, 
2001; Ding et al, 1990; Tsunawaki et al, 1988).  However, the effect may be 
caused though the suppression of production of other cytokines (Méndez-
Samperio et al, 2002; Chantry et al, 1989).  
Cell surface molecules on the surface of leukocytes are identified using a 
numbered cluster of differentiation (CD) system.  Currently there are over 350 
human CD molecules listed in the Human Cell Differentiation Molecules Council 
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website.  CD molecules can act in various ways such as cell signaling, cell 
adhesion, and as receptors and ligands.  When stimulated or differentiated, 
leukocytes usually vary their expression of various cell surface molecules.  
CD54, also known as Intra-Cellular Adhesion Molecule 1 (ICAM-1), is 
important in adhesion between endothelial cells and leukocytes, allowing the 
leukocyte to transmigrate to site of injury or inflammatory response.  It is usually 
expressed at a low level (van de Stolpe and van der Saag, 1996), however it is 
upregulated by cytokine stimulation, and may enhance this adhesion (Arkusz et 
al, 2010; Xie and Gu, 2008; Bella et al, 1998).  CD58 or Lymphocyte Function-
Associated Antigen 3 (LFA-3) is another cell adhesion molecule expressed on 
APCs, especially macrophages (Wallich et al, 1998; Barbosa et al, 1986), and is 
important in adhesion of T cells to APCs (Zhu et al, 2006; Wang et al, 1999).  
CD80 and CD86 (also called B7.1 and B7.2, respectively) are co-stimulatory 
molecules necessary to prime T cells responding to antigens presented by APCs 
(Slavik et al, 1999; Laniet et al, 1995).  Both provide regulatory signals for           
T lymphocytes after binding to CD28 (stimulatory signal) and CTLA4 (cytotoxic  
T-lymphocyte-associated protein 4) (inhibitory signal) receptors (Magistrelli et al, 
1999; Waterhouse et al, 1995).  CD11b or Integrin alpha M (ITGAM), together 
with CD18, forms the heterodimeric integrin αMβ2, also known as macrophage-1 
antigen (Mac-1) or complement receptor 3 (Solovjov et al, 2005).  Mac-1 is found 
on natural killer cells, granulocytes and mononuclear phagocytes such as 
macrophages and increased CD11b expression can be used as a marker for 
U937 differentiation to the macrophage stage (Saeki et al, 2003).  Genes for 
21 
 
CD54, CD58, CD80/CD86 and CD11b can be found on chromosomes 19, 1, 3 
and 16, respectively.  
Together these markers can provide a profile of the immunological effects 
of these ferments on the immune system and monocyte/macrophage activity.   
Objectives 
The key objective of this work was to examine the immunomodulatory 
effects of soy and milk ferments prepared with selected LAB strains on the 
activity of two key players in the innate immune system – the monocyte and 
macrophage.  We hypothesized that the effects of soy and milk ferments on IL-8, 
IL-10 and TGF-β1 secretion, as well as CD54, CD58, CD80 and CD86 
expression by U937 cells would not necessarily be the same on this cell type at 
different stages of differentiation.  To explore this hypothesis, the U937 cell line 
able to differentiate from the monocyte to the macrophage stage was used, and 
the effects of soy and milk ferments at the monocyte and the ATRA-differentiated 
macrophage stage were determined.  We also hypothesized that the responses 
of these cells to soy and milk ferment treatment under microgravity conditions 
would not necessarily be identical to those observed under regular gravity 
conditions. This aspect was examined using a HARV.  Ultimately, a fermented 
product that could be utilized by astronauts to maintain and improve their 
immune system while in flight would be an advantageous addition to the 
astronaut diet. This work aimed to provide some initial steps toward development 
of such a fermented product. 
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MATERIALS AND METHODS 
Ferment Preparation 
 Strains Lactobacillus helveticus R0052 (R0052), Bifidobacterium longum 
R0175 (R0175), and Streptococcus thermophilus ST5 (ST5) were used for the 
fermentation process. Soy beverage (SB) and milk beverage (MB) was prepared 
as reported previously (Champagne et al, 2009). Briefly, SB was prepared by 
soaking 250 g of dried soybeans in distilled water overnight, and 190 g of soaked 
beans plus 500 mL of fresh distilled water were ground with a commercial 
blender unit (Waring, New-Hartford, USA) for 3 min, filtered on Whatman #4 
membranes and boiled for 5 min, cooled in an ice bath and stored at 4°C.  MB 
was prepared by adding 61.9 g of skim milk powder (Crino, Agropur, Granby QC, 
Canada) to 715 mL of 3.25% milk fat commercial milk (Lactantia Pur Filtre, 
Parmalat, Victoraville, QC, Canada) and adding water to make 1 L. This milk 
blend was then boiled for 5 min, cooled in an ice bath and stored at 4°C.  These 
lab-made beverages were inoculated with 1×107 CFU/mL ST5 and either 1×107 
CFU/mL of R0175 or R0052.  In addition to these ferment preparations, an 
unfermented SM and MB control was included to separate effects of dairy milk 
and soy milk alone, and a lactic acid acidified (pH of 4.70 ± 0.1) SM and MB 




Cultures and controls were incubated at 37°C until a pH of 4.70 ± 0.1 was 
reached or for a maximum of 24 hours. A total of 12 mL cultures and controls 
were placed into 15-mL screw-capped conical tubes (Starstedt, Newton, N.C., 
U.S.A.), cooled in an ice water bath for 30 minutes, and then frozen at -80°C in a 
cabinet air freezer (Thermo Forma model 995, Marietta, Ohio, U.S.A.) for          
24 hours. The frozen cultures and controls were shipped in dry ice by rapid 
courier (less than 24 hours) and then maintained at -80°C until tested for 
bioactivity. 
Since cultures were prepared in one site and tested in another, it was 
necessary to freeze and store samples. Preliminary studies determined the 
effects of fermentation substrate and storage on culture viability (Wagar et al, 
2009).  The 15 mL tubes were removed from -80°C, partially thawed and 
aseptically divided into aliquots, on ice to prevent a complete thaw, into 1.5 mL 
tubes (approximately 400 μL per tube) and immediately refrozen.  For assays, 
aliquots were removed from -80°C and thawed at room temperature.  Thawed 
ferments were aseptically homogenized using a Dremel® 4.8V MiniMite Cordless 
(Bosch Gear, Madison Heights, M.I., U.S.A.; model #750) power tool fitted with a 
conical blending attachment (See Appendix E), set to “HI” for approximately 5 to 
10 seconds.  Ferment dilutions were carried out in RPMI 1640. 
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 Cell Culture  
 All reagents used for cell culture were supplied by Sigma-Aldrich Canada 
unless otherwise noted.  All cells were grown in 250 mL, 75 cm2 tissue culture 
flasks (Cellstar, Greiner Bio-One, Mississauga, Ontario, Canada).  Cultures were 
maintained at 37°C, 5% CO2 in a humidified incubator (Thermo Corporation, 
Toronto, Canada). 
The THP-1 monocytic leukemia suspension cell line (ATCC# TIB-202) 
was obtained from the American Type Culture Collection (ATCC).  Cultures of 
THP-1 were maintained in media consisting of RPMI 1640 medium 
supplemented with 10% FBS, 0.05 mM β-mercaptoethanol, and 0.05 mg/mL 
gentamycin sulphate.  Sub-culturing of cells was carried out every 6-7 days by 
rinsing the bottom face of the flask with already-present growth media.  
Approximately 50% of the media in the flask was transferred to a new flask, at an 
inoculation of approximately 50% by volume.  In preparation for bioassays, 
growth media was removed by centrifugation at 300 × g at 4°C for 10 minutes.  
Cell pellets were resuspended in RPMI 1640.  
The U937 histiocytic lymphoma suspension cell line (ATCC# CRL-1593.2) 
was obtained from the ATCC. Cultures of U937 cells were maintained in media 
consisting of RPMI 1640 medium supplemented by 10% FBS, 1 mM sodium 
pyruvate, 0.05 mM β-mercaptoethanol, 2 mM L-glutamine and 0.05 mg/mL 
gentamycin sulphate.  Sub-culturing of cells was carried out every 2-4 days by 
rinsing the bottom face of the flask with the already-present growth media.  
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Approximately 20-50% (depending on cell confluency) of the media in the flask 
was transferred to new flasks, at an inoculation of approximately 20-50% by 
volume.  In preparation for bioassays, growth media was removed by 
centrifugation at 300 × g at 4°C for 10 minutes.  Cell pellets were resuspended in 
RPMI 1640 media. 
U937 TNF-α Challenge Kinetics 
 U937 monocytes were seeded in 96 well cell culture plate (Cellstar, 
Greiner Bio-One) at a concentration of 1 × 106 cells/mL and challenged at a final 
concentration of 5 × 105 cells/mL at initial viabilities greater than 80% (as 
determined by a Trypan-blue exclusion count (Sigma-Aldrich Canada)).  A range 
of concentrations of TNF-α (PeproTech, Rocky Hill, N.J., U.S.A., Catalogue             
#300-01A) (1 ng/mL, 20 ng/mL, 50 ng/mL, 100 ng/mL and 200 ng/mL) were 
tested to determine the optimal concentration for IL-8 induction.  Cells were 
incubated with TNF-α at 37°C, 5% CO2 for 4 hours.  The lowest concentration of 
TNF-α which induced the greatest amount of IL-8 was used in all subsequent 
challenges.  When an optimal concentration had been established, two additional 
time points (8 hours and 24 hours) was used to determine the time of optimal IL-
8 production, using the established concentration of TNF-α.  Plates were 
centrifuged at 300 × g for 10 minutes, supernatants aspirated, moved to a new 
plate and stored at -80°C until assayed.  The time of incubation which produced 
the greatest amount of IL-8 was used in all subsequent challenges. 
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THP-1 LPS Challenge Kinetics 
 Monocytic THP-1 cells were seeded in 96 well cell culture plate (Cellstar, 
Greiner Bio-One) at a concentration of 1 × 106 cells/mL and challenged at a final 
concentration of 5 × 105 cells/mL at initial viabilities greater than 80% (as 
determined by a Trypan-blue exclusion count (Sigma-Aldrich Canada)).  A range 
of concentrations of LPS serotype 026:B6 (Sigma-Aldrich Canada, Catalogue         
#L2654) (1 ng/mL, 50 ng/mL, 100 ng/mL, 250 ng/mL, 500 ng/mL and 1000 
ng/mL) were tested to determine the optimal concentration of IL-8 induction.  
Cells were incubated with LPS at 37°C, 5% CO2 for 4 hours.  The lowest 
concentration of LPS which induced the greatest amount of IL-8 was used in all 
subsequent challenges.  When the optimal concentration had been established, 
two additional time points (8 hours and 24 hours) was used to determine the time 
of optimal IL-8 production, using the established concentration of LPS.  Plates 
were centrifuged at 300 × g for 10 minutes, supernatants aspirated, moved to a 
new plate and stored at -80°C.  The time of incubation which produced the 
greatest amount of IL-8 was used in all subsequent challenges. 
Cytokine Kinetics 
 IL-8 protein had been previously shown to be optimally produced by    
TNF-α-treated U937 cells at 24 hours, so no time course was performed for this 
cytokine (See Results - Optimization of Cell Line and Stimulus Approaches for 
Testing Soy and Milk Ferment Bioactivity). 
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TNF-α challenged cells were seeded in 96 well cell culture plate (Cellstar, 
Greiner Bio-One) at a concentration of 1 × 106 cells/mL and challenged at a final 
concentration of  5 × 105 cells/mL at initial viabilities greater than 85% (as 
determined by Guava ViaCount Assay) and incubated for 24 hours, 48 hours and 
72 hours.  Plates were centrifuged at 300 × g for 10 minutes, supernatants 
aspirated then moved to a new plate and stored at -80°C.  Supernatant 
designated for TGF-β1 ELISAs were placed in 96 well plates siliconized with 
SigmaCote® (Sigma-Aldrich Canada, Catalogue #SL2) to prevent TGF-β1 from 
adsorbing to the plates.  Incubation times which produced optimal cytokine 
concentrations were used in all subsequent challenges. 
U937 Differentiation Assay 
Three different agents were compared for their effects on U937 
differentiation: Phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich Canada, 
Catalogue #P1585), 1,25-dihydroxyvitamin D3  (vitamin D3; Sigma-Aldrich 
Canada, Catalogue #D1530) or all-trans retinoic acid (ATRA; Sigma-Aldrich 
Canada, Catalogue #R2625).  As shown in Table 2, the most consistently used 
final concentrations of PMA, vitamin D3 and ATRA for monocyte differentiation 
are 0.16 μM, 0.1 μM and 1 μM, respectively.  100x stock solutions were initially 
prepared in anhydrous ethyl alcohol and stored at -20°C.  From this, 10x stocks 
were prepared in RPMI 1640 to a final volume of 1000 μL and stored at -20°C.  A 
1/10 dilution of the 10x stock was made by diluting with 1 × 106 cells/mL U937 
cell culture suspension and incubated for 24 hours and 48 hours at 37°C,          
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5% CO2 in a 24 well plate.  Differentiation was confirmed by immunophenotyping 
for increased CD11b expression (see Cell Surface Marker Expression section), in 
order to determine which agent was most effective.  Differentiated U937s were 
not passaged; new batches of cells were prepared each time as follows: 1000μL 
(one tube) of 10x stock was added to 9 mL of U937 cell suspension at a 
concentration of approximately 5 × 105 - 1 × 106 cells/mL and incubated in a new 
T-75 flask for the specified incubation time.  In preparation for bioassays, growth 
media containing the differentiation agent was removed by centrifugation at    
300 × g at 4°C for 10 minutes.  Cell pellets were resuspended in RPMI 1640 
media. 
Normal Gravity Ferment Bioassays 
 TNF-α challenged non-differentiated monocytic or differentiated 
macrophage-like U937 cells were seeded in 96 well or 24 well cell culture plates 
(Cellstar, Greiner Bio-One) at concentration of 1 × 106 cells/mL (1 × 105 cells per 
well) at initial viabilities greater than 80% (as determined by a Trypan-blue 
exclusion count (Sigma-Aldrich Canada) or Guava ViaCount assay).  100 μL of 
diluted ferments and controls were added, for a final cell density of 5 × 105 
cells/mL and ferment/control dilution of 1/100.  Cells were incubated at 37°C, 5% 
CO2 for previously determined lengths of time.  Plates were centrifuged at        
300 × g for 10 minutes, supernatants aspirated then moved to a new plate and 
stored at -80°C until assayed.  Supernatant designated for TGF-β1 ELISAs were 
placed in 96 well plates siliconized with SigmaCote®. 
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Simulated Microgravity Ferment Bioassays 
TNF-α challenged non-differentiated monocytic or differentiated 
macrophage-like U937 cells were diluted to a density of 5 × 105 cells/mL at initial 
viabilities greater than 80% (as determined by Guava ViaCount assay).  An equal 
volume of diluted ferments and controls were added, for a final cell density of   
2.5 × 105 cells/mL and ferment/control dilution of 1/100.  This cell mixture was 
seeded into a disposable 10 mL HARV cell culture vessel, at a vessel rotation 
speed of ~15 rpm (personal communication, M. Hughes-Fulford), and incubated 
at 37°C, 5% CO2 for the optimal time determined for each cytokine/cell surface 
marker.  Cell suspensions were collected in a 15 mL conical tube and centrifuged 
at 300 × g for 10 minutes.  Aliquots of supernatant were placed into 1.5 mL 
Eppendorf tubes and stored at   -80°C until assayed.  Supernatant designated for 
TGF-β1 ELISAs were placed in 1.5 mL Eppendorf tubes siliconized with 
SigmaCote®. 
Quantification of IL-8, TGF-β1, and IL-10 protein by ELISA 
All buffers and reagents were prepared and used in accordance with the 
manufacturer’s protocol for IL-8 (BioSource, San Diego, California, Catalogue         
#CHC1303), TGF-β1 (R&D Systems, Minneapolis, Minnesota, Catalogue               
#DY240),  and IL-10 (BioSource, Catalogue #CHC1323) ELISA (Enzyme-linked 
Immunosorbent Assay) kits.  Polystyrene, high binding, Microlon® 600 ELISA 
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plates (Greiner bio-one, Catalogue #655061) were used for all ELISA assays. 
Table 3 compares buffer compositions and protocols for each ELISA kit. 
For the IL-8 ELISA, capture antibody was used at a concentration of         
1 µg/mL in coating buffer. The working concentration of biotinylated anti- Human 
IL-8 detection antibody was 0.04 µg/mL. Horseradish peroxidase (HRP)-
conjugated streptavidin was used at a 1/2500 dilution.  1.8 N H2SO4 was used as 
a stop solution. 
For the TGF-β1 ELISA, capture antibody was used at a concentration of 
2.0 µg/mL in phosphate buffered saline (PBS).  Samples were first acidified with 
one part 1 N HCl to 5 parts sample for 10 minutes, then neutralized with a 
volume equal to that of the acid of 1.2 N NaOH/0.5 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES).  The working concentration of 
biotinylated chicken anti-human TGF-β1 was 300 ng/mL.  HRP-conjugated 
streptavidin was used at 1/200 dilution.  2 N H2SO4 was used as a stop solution. 
For the IL-10 ELISA, capture antibody was used at a concentration of        
1 µg/mL in coating buffer. The working concentration of biotinylated anti- human 
IL-10 detection antibody was 0.16 µg/mL. HRP-conjugated streptavidin was used 
at a 1/1250 dilution.  1.8 N H2SO4 was used as a stop solution. 
Human recombinant IL-8, TGF-β1 and IL-10 were used as standards in all 
ELISAs and all plates were read at a wavelength of 450 nm (reference 
absorbance: 650 nm) using a plate reader (Bio-Tek Instrumentation, Nepean, 
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Ontario), data collected with KC4 program for Windows (Bio-Tek) and compiled 
using Microsoft® Excel® (Microsoft Corp., Redmond, Wash., U.S.A.). 
Cell Viability – Guava ViaCount Assay 
 A Millipore® Guava Personal Cell Analysis (PCA; Millipore, Billerica, MA, 
Catalogue #0500-1090) was used for all ViaCount assays.  Cytosoft™ Software 
was used for data acquisition and analysis.  The Guava PCA Instrument contains 
a laser, which operates at 532 nm and emits 7 mW visible laser radiation.  
ViaCount Reagent (Millipore, Catalogue #4000-0041) differentially stains viable 
and non-viable cells.  Two dyes are used (a membrane-permeable dye that 
stains all nucleated cells, and another membrane-impermeable dye that stains 
damaged cells) to discriminate between viable and non-viable cells.  The Guava 
PCA then detects forward angle light scatter to distinguish between free nuclei 
and cellular debris to give an accurate total and viable cell count.  The Cytosoft™ 
software utilizes an “EasyFit” feature, which uses a computer-assisted population 
analysis method, in lieu of traditional cell gating.  EasyFit allows better 
discrimination between viable cells, non-viable cells and debris when those 
populations overlap because the analysis is performed in three dimensions.  This 
is useful when there is debris in the sample, such as ferment particulates and 
bacteria.   
 For viability assays, 560 μL of 1 × 106 cells/mL cell suspension was added 
to a 24 well plate.  Dilutions of ferments and controls were added for a final 
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ferment/control dilution of 1/100 and a final cell concentration of 5 × 105 cells/mL.  
Plates were incubated for 24 hours at 37°C, 5% CO2.  Cells from HARV vessels 
were collected after centrifugation.  Samples which contained large, visible debris 
were filtered though a BD Falcon™ 70 μm cell strainer (BD Biosciences, San 
Jose, C.A., U.S.A., Catalogue #352350).  Cell samples were diluted 1/20 with 
ViaCount Reagent and incubated at room temperature for 5 minutes.  The Guava 
PCA was calibrated before reading samples using the Guava Check software 
and Guava Check kit (Millipore, Catalogue #4500-0020).  Data was collected 
(1000-2000 events collected) using the Guava ViaCount software, and exported 
to Microsoft® Excel® for analysis. 
Cell Surface Marker Expression – Guava Express Assay 
 A Millipore® Guava PCA was used for all cell surface marker assays.  
Cytosoft™ Software was used for data acquisition and analysis.   The Guava 
Express assay uses two fluorescence parameters along with forward scatter to 
identify cells expressing specific cell surface molecules.  Fluorophore-conjugated 
antibodies are able to bind to specific surface molecules on the cells, labelling 
them, and the Guava PCA can detect the intensity of fluorescence labels on 
individual cells and the number of cells labelled. 
 560 μL of 1 × 106 cells/mL cell suspension was added to a 24 well plate.  
Dilutions of ferments and controls were added for a final ferment dilution of 1/100 
and a final cell concentration of 5 × 105 cells/mL.  Plates were incubated for 24 
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hours at 37°C, 5% CO2.  Samples which contained large, visible debris were 
filtered though a BD Falcon™ 70 μm cell strainer (BD Biosciences, Catalogue 
#352350).  1 × 106 pre-treated cells in a volume of 100 μL to 300 μL were added 
to a 1.5 mL tube and centrifuged at 300 × g for 10 minutes.  Cell media was 
aspirated and cell pellet resuspended in 100 μL to 150 μL Double Protein Cell 
Staining Buffer (DPCSB; 5% FBS, 5% BSA in PBS, pH 7.4).  10-15 μL of 0.5 
mg/mL human IgG1, κ (Sigma-Aldrich Canada, Catalogue #I5154) or human 
IgG2, κ (Sigma-Aldrich Canada, Catalogue #I5404), as appropriate (See Table 
4), were added (to block non-specific binding though Fc receptors and reduce 
background) and incubated for 10 minutes.  20 μL of phycoerythrin (PE) labeled 
anti-CD54 (BioLegend, San Diego, CA, Catalogue #322708), PE labeled anti-
CD58 (BioLegend, Catalogue #322506), PE labeled anti-CD80 (BioLegend, 
Catalogue #305208), PE labeled anti-CD86 (BioLegend, Catalogue #305406) or 
PE labeled anti-CD11b (BioLegend, Catalogue #301306) were added to the cell 
suspension, carried out in a darkened laminar flow hood.  PE labeled mouse 
IgG1, κ (BioLegend, Catalogue #400114) and PE labeled mouse IgG2b, κ 
(BioLegend, Catalogue #400314) isotype control antibodies, as appropriate (See 
Table 4), were added to separate tubes as an internal control.  Labeled cell 
suspensions were incubated on ice, in the dark, for 30 minutes.  To remove non-
specific binding, cells were washed twice in 1 mL DPCSB, then resuspended in 
400 μL of DPCSB (or less if the cell pellet was particularly small), and incubated 
for  5 minutes on ice, in the dark.  Data was collected using the Guava Express 
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software (2000 events collected), and exported to Microsoft® Excel® for analysis.  
Results are reported in mean fluorescence intensity (MFI). 
Statistical Analysis 
Data presented as means ± standard error of the mean (SEM) was 
analyzed using a one-way analysis of variance (ANOVA).  Pre-treatment or 
negative control data (with the exception of viability results) was excluded from 
the ANOVA. Results indicating significance (values of p < 0.05) were then 
analyzed using Tukey-Kramer Multiple Range Test for further comparison of 
means.  If a Tukey-Kramer Multiple Range Test was not able to delineate 
differences, a Dunnett’s post test was used, with challenged cell controls as the 
comparison. 
For ELISAs, each sample was tested in triplicate in each ELISA and 
assigned an average value. Therefore, a value represented as n = 1 is equivalent 











Optimization of Cell Line and Stimulus Approaches for Testing Soy 
and Milk Ferment Bioactivity 
 
U937 monocytes required 20 ng/mL of TNF-α for optimal IL-8 production 
(Figure 1), with a 24 hour incubation time (Figure 2).  THP-1 monocytes required 
100 ng/mL LPS (Figure 3), also with a 24 hour incubation time (Figure 4). 
 A 48 hour incubation time was required for optimal TGF-β1 production.    
IL-10 concentrations produced by U937s or differentiated U937s at normal 
gravity were below the limit of detection by ELISA and although initially tested for, 
were not considered for further study.   
 Although initial results suggested that milk ferments prepared with ST5 + 
R0175 decreased IL-8 production in LPS-challenged THP-1 monocytes      
(Figure 5), it was noted that unfermented milk controls had marked effects 
suggesting THP-1 responses to milk controls.  The THP-1 cell line also grows 
very slowly compared to U937s.  In addition, the U937 cell line is noted for its 
ability to be differentiated to macrophage stage in response to several 
differentiation agents.  For these reasons, the U937 line was selected for further 
study of the effects of soy and milk ferments at different stages of differentiation. 
 Effects of soy and milk ferments and controls were initially tested at a 
dilution range of 1/10, 1/100 and 1/1000 for their effects on TNF-α-induced IL-8 
production by non-differentiated U937 cells.  At a 1/10 dilution, soy and milk 
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controls had marked effects on IL-8 production, and at a 1/1000 dilution, ferment 
effects were diluted out (data not shown).  Therefore the 1/100 dilution was 
selected for further study of the effects of soy and milk ferments. 
U937 Cells Can Be Differentiated by All-Trans Retinoic Acid 
U937 monocytic cells incubated with 1 μM ATRA for 24 hours showed the 
greatest increase in CD11b expression (Figure 6), and were chosen for future 
study.  Treatment with 0.16 µM PMA for 24 and 48 hours did not increase CD11b 
expression, and treatment with 0.1 µM Vitamin D3 for 24 and 48 hours did not 
increase CD11b expression to the extent of treatment with 1 µM ATRA.  48 hour 
treatment with PMA, ATRA or Vitamin D3 did not increase CD11b expression 
compared to 24 hour treatment.  For this reason, a 24 hour incubation with 1 µM 
ATRA was chosen as the optimal differentiation agent for U937 treatments. 
Effects of Soy and Milk Ferments on Cytokine Production by Non-
Differentiated and Differentiated U937 Cells 
 
IL-8 production by non-differentiated U937s in response to TNF-α was not 
significantly affected by the presence of milk ferments or controls (Figure 7).  
However, soy ferment prepared with ST5 + R0175 did significantly decrease IL-8 
production relative to TNF-α treated controls (Figure 8).  Soy controls and soy 
ferment prepared with ST5 + R0052 also decreased IL-8 production to some 
extent but this did not reach statistical significance.  In contrast, milk ferments 
significantly decreased IL-8 production by differentiated U937 cells (Figure 9) 
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relative to unfermented milk and acidified milk controls but not relative to TNF-α 
treated cell controls.  Differentiated U937s treated with TNF-α and milk controls 
produced surprisingly high levels of IL-8, and this effect was also observed for 
differentiated U937s treated with soy controls.  While milk ferments produced a 
decrease in IL-8 production relative to the milk controls, differentiated U937s 
treated with soy controls and soy ferments did not show this same decrease in 
TNF-α-induced IL-8 production (Figure 10). 
Constitutive TGF-β1 production by differentiated U937 cells was higher 
than for non-differentiated U937 cells.  While TNF-α treatment increased TGF-β1 
production by non-differentiated U937s, it had the opposite effect on 
differentiated U937s (Figure 11).  
TGF-β1 secretion by non-differentiated U937s was significantly decreased 
by milk ferments and milk controls relative to TNF-α treated control cells (Figure 
12) but was not significantly decreased by soy ferments or soy controls (Figure 
13).  In contrast, soy ferments decreased TGF-β1 secretion by differentiated 
U937s relative to acidified soy controls but not relative to challenged controls 
(Figure14).  Milk ferments or milk controls did significantly not affect TGF-β1 
secretion by differentiated U937s (Figure 15). 
Effects of Soy and Milk Ferments on Cell Viability by Non-
Differentiated and Differentiated U937 Cells 
 
Viability of non-differentiated U937s was significantly decreased by milk 
fermented with ST5 + R0052 (Figure 16) but not by soy fermented with these 
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strains (Figure 17).  Viability of differentiated U937 cells was not significantly 
affected by the presence of milk ferments or controls (Figure 18).  Minor effects 
were noted with soy ferments, as indicated by a significant ANOVA result           
(p = 0.0092) but no differences were detected by the Tukey-Kramer multiple 
range test (Figure 19).  The ANOVA result may reflect slightly lower viability of 
ferments relative to soy controls, as the soy controls values appear slightly higher 
than the challenged control values.  However, the ferments did not appear to 
decrease viability to any marked extent relative to TNF-α treated controls (Figure 
19).  
Effects of Soy and Milk Ferments on Cell Surface Marker Expression 
on Non-Differentiated and Differentiated U937 Cells 
 
Soy controls and soy ferments significantly down-regulated CD54 
expression on non-differentiated U937 (Figure 20).  Milk ferments significantly 
down-regulated CD54 expression on non-differentiated U937s (Figure 21) 
(Dunnett’s post test used to show why ANOVA was significant), while milk 
controls had no significant effect. 
Overall, the MFI for CD58 was lower than the MFI for CD54, reflecting a 
lower level of expression of this cell surface molecule.  Soy ferments significantly 
decreased CD58 expression on non-differentiated U937s relative to TNF-α 
treated controls (Figure 22), although some decrease was also observed with 
soy controls.  There was a trend (p = 0.0644) towards milk ferments decreasing 
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CD58 expression on non-differentiated U937s (Figure 23) and the overall pattern 
of the response was similar to that observed for effects on CD54 expression. 
On differentiated U937s, CD54 expression was significantly decreased by 
milk ferments and soy controls and ferments (Figure 24 and 25). CD58 
expression was significantly decreased by soy ferments (Figure 26) although soy 
controls also decreased expression, and there was a trend (p = 0.0788) towards 
milk ferments decreasing CD58 expression on differentiated U937s (Figure 27). 
CD80 expression was not affected by any ferments or controls at either 
differentiation stage (Figure 28, 29, 30 and 31) and levels of CD80 expression 
were essentially negative for all conditions tested.  
There was some increase in CD86 expression by TNF-α treated controls 
for both non-differentiated U937s and differentiated U937s.  The highest levels of 
CD86 expression were observed with TNF-α treated differentiated U937s, where 
the MFI was 132.3 (isotype background subtracted), relative to an MFI of 20.5 
(isotype background subtracted).  This increase was not observed when either 
milk or soy ferments or controls were added, suggesting some decrease in CD86 
expression due to treatment.  With respect to differentiated U937s, addition of 
soy ferments decreased the MFI, while milk ferment addition decreased the MFI, 
even though this was not statistically significant (Figure 32, 33, 34 and 35). 
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Effects of Soy and Milk Ferments on Cytokine Production by Non-
Differentiated and Differentiated U937 Cells under Simulated 
Microgravity Conditions 
 
Soy ferments did not affect IL-8 production by non-differentiated or 
differentiated U937s in simulated microgravity (Figure 36 and 37) but there was 
some decrease observed for non-differentiated U937s treated with milk controls 
and ferments (Figure 38).  Milk fermented with ST5 + R0052 significantly 
decreased IL-8 production by differentiated U937s compared to treatment with 
acidified milk controls (Figure 39). 
Conversely, milk controls and ferments did not affect TGF-β1 production 
by non-differentiated or differentiated U937s (Figure 40 and 41).  There was a 
trend (p = 0.0582) towards soy ferments decreasing TGF-β1 by non-
differentiated U937s (Figure 42), and a slight decrease in TGF-β1 production by 
differentiated U937s treated with unfermented soy and both ferments (Figure 43), 
although this was not statistically significant. 
Effects of Soy and Milk Ferments on Cell Viability of Non-
Differentiated and Differentiated U937 Cells under Simulated 
Microgravity Conditions  
 
 Soy controls and ferments did not significantly affect non-differentiated or 
differentiated U937 cell viability (Figure 44 and 45).  Milk fermented with ST5 + 
R0175 significantly decreased cell viability compared to challenged cell control in 
differentiated U937s (Figure 46).   Milk fermented with ST5 + R0052 decreased 
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non-differentiated U937 cell viability (Figure 47).  As the Tukey-Kramer post test 
did not delineate the differences between conditions, even though the ANOVA 
was significant, a Dunnett’s post test was used to determine the reason why the 
ANOVA was significant. 
Effects of Soy and Milk Ferments on Cell Surface Marker Expression 
in Non-Differentiated and Differentiated U937 Cells under 
Simulated Microgravity Conditions 
 
In non-differentiated U937s, soy controls and soy ferments showed a 
trend (p = 0.0856) to decreased CD54 expression (Figure 48).  Both milk 
ferments decreased CD54 expression from 1058.1 MFI in TNF-α treated controls 
to between 268.5 for milk fermented with ST5 + R0175 to 282.2 for milk 
fermented with ST5 + R0052, although this was not statistically significant (Figure 
49).  In differentiated U937s, there is also a trend (p = 0.0800) towards soy 
controls and soy ferments decreasing CD54 expression (Figure 50) while 
acidified milk and both milk ferments showed a significant decrease in CD54 
expression compared to TNF-α challenged controls (Figure 51).  
Soy and milk controls and ferments all significantly decreased CD58 
expression by non-differentiated U937s (Figure 52 and 53) although the lowest 
MFI levels were observed for cells treated with milk ferments (Figure 53).  
Differentiated U937s treated with acidified soy and both soy ferments had 
decreased CD58 expression (Figure 54) (Dunnett’s post test used to show why 
ANOVA was significant).  There was a significant decrease in CD58 expression 
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when treated with acidified milk and both milk ferments (Figure 55) while 
unfermented milk controls had no effect. 
CD80 expression was not affected in non-differentiated or differentiated 
U937s by either milk or soy controls or ferments (Figure 56, 57, 58 and 59). 
In non-differentiated U937s, there was a slight increase in CD86 
expression in the TNF-α challenged control, but this was not observed for U937s 
treated with in soy or milk controls or ferments (Figure 60 and 61).  CD86 
expression by non-differentiated U937 cells treated with soy ferment prepared 
with ST5 + R0175 was low (MFI = 8.5, isotype subtracted), in contrast to 
challenged cell control MFI values (MFI = 37.9, isotype subtracted), even though 
this was not statistically significant.  However for differentiated U937s, there was 
a significant decrease in CD86 expression by cells treated with soy and milk 






Table 1: Summary of selected current literature concerning use of HARV cell 
culture vessels to simulate microgravity including cell type and duration of 
culture. 
 
Cell type Duration of incubation 
Bioreactor 
Vessel Author(s) 
Human IEC cell line Int-
407 28-32 days HARV Nickerson et al, 2001 
Murine myoblast cell line 
C2C12 cells  6+ days 10 ml HARV Marquette et al, 2007 
Peripheral Blood 
Mononuclear Cell (PBMC) 6 days RWV Bruno et al, 2006 
Primary keratocytes from 
fresh bovine eyes 19 days 50 ml HARV Chen et al, 2007 
E. coli MG1655 "least ten generations" 50 ml HARV Tucker et al, 2007 
Human peripheral blood 
lymphocytes up to 24h 
50 ml/10 ml 
HARV Mognato et al, 2009 
PBMC 24h RWV Ward et al, 2006 
PBMC up to 96h RWV Sundaresan et al, 2004 
PBMC -- 10 ml HARV Ritz et al 2005 
PBMC 24 or 72 h (not clear) Sundaresan and Pellis, 2009 
T- and B-lymphocytes 4h, 72h, 7 d Clinostat Kumari et al, 2009 









Table 2: Summary of the current literature concerning commonly used U937 
monocytic cell differentiation agents, concentrations used, duration, and cell 
surface marker used to confirm differentiation. 
 
Differentiation 
Agent Con'c Duration 
Macrophage 
Marker Author(s) 
ATRA 1 μM 24h CD11b Zhang et al, 2008 
ATRA 1 μM - - Witcher et al, 2008 
PMA 50 ng/mL 48h - Tahan et al, 2008 
PMA 100 ng/mL 48h - Sintiprungrat et al, 2010 
VitD3 0.1 μM 4h CD11b Liu et al, 1996 
VitD3 0.1 μM 24h CD14 Liu et al, 2005 
PMA 0.16 μM > 24h CD14 Kulseth et al, 1997 
ATRA 1 μM > 24h CD14 Kulseth et al, 1997 
VitD3 0.1 μM > 24h CD14 Kulseth et al, 1997 
ATRA 1 μM 48h - Dimberg et al, 2006 
VitD3 0.1 μM 48h - Dimberg et al, 2006 
PMA 0.16 μM - - Zanocco-Marani et al, 2009 
ATRA 1 μM < 96h CD11b Yang et al, 2003 









Table 3: Composition of assay solutions for IL-8, TGF-β1 and IL-10 ELISA kits. 
 
Solution 
IL-8 TGF-β1 IL-10 
(Mass Per Litre) (Molar) (Mass Per Litre) 
Coating Buffer 
8.0 g NaCl, 1.13g 
Na2HPO4, 0.2g 
KH2PO4, 0.2g KCl, 
pH to 7.4 
137 mM NaCl, 2.7 
mM KCl, 8.1 mM 
Na2HPO4, 1.5 mM 
KH2PO4, pH 7.4, 0.2 
µm filtered 
8.0 g NaCl, 1.13g 
Na2HPO4, 0.2g 
KH2PO4, 0.2g KCl, 
pH to 7.4 
Assay Buffer 
8.0 g NaCl, 1.13 g 
Na2HPO4, 0.2 g 
KH2PO4, 0.2 g KCl, 
5.0 g BSA, pH to 7.4 
137 mM NaCl, 2.7 
mM KCl, 8.1 mM 
Na2HPO4, 1.5 mM 
KH2PO4, 1.4% BSA, 
0.05% Tween-20, pH 
7.4 
8.0 g NaCl, 1.13 g 
Na2HPO4, 0.2 g 
KH2PO4, 0.2 g KCl, 
5.0 g BSA, pH to 7.4 
Wash Buffer 
0.2 g KH2PO4, 1.9 g 
K2HPO4·3H2O, 0.4 g 
EDTA, 0.5 mL 
Tween-20, pH to 7.4 
137 mM NaCl, 2.7 
mM KCl, 8.1 mM 
Na2HPO4, 1.5 mM 
KH2PO4, 0.05% 
Tween-20, pH 7.4 
0.2 g KH2PO4, 1.9 g 
K2HPO4·3H2O, 0.4 g 
EDTA, 0.5 mL 
Tween-20, pH to 7.4 
Substrate Solution 1:1  H2O2:TMB 1:1  H2O2:TMB 1:1  H2O2:TMB 












Table 4: Isotype controls used for immunofluorescence analysis of cell surface 
marker expression on U937 cells. 
 
























Table 5:  Synopsis of effects on cytokine production, viability and cell surface 
molecule expression by non-differentiated and differentiated U937 cells in normal 
versus simulated microgravity conditions treated with milk and soy ferments.   
 
  
Normal Gravity Simulated Microgravity 
    IL-8 TGF-β1   IL-8 TGF-β1 
Non-differentiated 
U937 
Milk – ↓ Milk ↓ – 
Soy ↓ – Soy – ↓ 
Differentiated 
U937 
Milk ↓ – Milk ↓ – 
Soy – ↓ Soy – ↓ 
       
  Viability 
Non-differentiated 
U937 
Milk ↓ by Milk ST5 + R0052 Milk 
↓ by Milk ST5 + 
R0052 
Soy – Soy – 
Differentiated 
U937 
Milk – Milk ↓ by Milk ST5 + R0175 
Soy – Soy – 
       
  
  
CD54/   
58/86 CD80   




Milk ↓ – Milk ↓ – 
Soy ↓ – Soy ↓ – 
Differentiated 
U937 
Milk ↓ – Milk ↓ – 
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Figure 1.  Effect of TNF-α concentration on IL-8 production by non-differentiated 
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Figure 2. Time required for optimal IL-8 response by TNF-α challenged non-
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Figure 3.  Effect of LPS concentrations on IL-8 production by THP-1 monocytic 










Timing Required for Optimal IL-8 Response by 
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Figure 4.  Time required for optimal IL-8 response to LPS challenged THP-1 
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Figure 5:  Effect of soy and milk ferments and controls (1/100 dilution in RPMI 
1640) on IL-8 production by THP-1 monocytic cells (5 × 105 cells/mL) in the 
presence of 100 ng/mL LPS following concurrent incubation for 24 hours.  Data 
shown as mean concentration in pg/mL ± SEM (n = 3).  Unchallenged cell control 
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Figure 6: Effects of PMA, Vitamin D3 and ATRA on U937 monocytic cell 
differentiation following incubation.  U937 cells were collected after 24 hours and 
48 hours and tagged with PE labeled anti-CD11b antibodies.  Data shown as 
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Figure 7:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 1640) 
on IL-8 production by non-differentiated U937 monocytic cells (5 × 105 cells/mL) 
in the presence of 20 ng/mL TNF-α following concurrent incubation of 24 hours.  
Data shown as mean concentration in pg/mL ± SEM. (One-way ANOVA;             





IL-8 Production by TNF-α Challenged U937 Monocytic

























































Figure 8:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on IL-8 production by non-differentiated U937 monocytic cells (5 × 105 cells/mL) 
in the presence of 20 ng/mL TNF-α following concurrent incubation for 24 hours.  
Data shown as mean concentration in pg/mL ± SEM) (One-way ANOVA;             
p = 0.0390; n = 4 for challenged cell controls and unchallenged cell controls,        
n = 6 for soy controls and soy ferments).  Unchallenged cell control produced 
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Figure 9:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 1640) 
on IL-8 production by ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as log10 concentration in pg/mL ± SEM. (One-way 
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Figure 10:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on IL-8 production by ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as log10 concentration in pg/mL ± SEM. (One-way 
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Figure 11: Comparison of TGF-β production by non-differentiated and 
differentiated U937 cells, unchallenged or challenged with 20 ng/mL TNF-α 
following concurrent incubation for 48 hours.  Data shown as mean concentration 
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Figure 12:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on TGF-β1 production by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
48 hours.  Data shown as mean concentration in pg/mL ± SEM.  (One-way 
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Figure 13:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on TGF-β1 production by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
48 hours. Data shown as mean concentration in pg/mL ± SEM.  (One-way 
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Figure 14:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on TGF-β1 production by ATRA-differentiated U937 macrophage-like cells (5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 48 hours.  Data shown as mean concentration in pg/mL ± SEM.  (One-way 
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Figure 15:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on TGF-β1 production by ATRA-differentiated U937 macrophage-like cells 
(5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 48 hours.  Data shown as mean concentration in pg/mL ± SEM.  
(One-way ANOVA; p = 0.1349; n = 6).  Unchallenged cell control produced 218.8 
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Figure 16: Viability of non-differentiated U937 monocytic cells (5 × 105 cells/mL) 
following concurrent incubation with milk ferments and milk controls (1/100 in 
RMPI 1640) and 20 ng/mL TNF-α for 24 hours.  Data shown as mean percent 
viability ± SEM.  (One-way ANOVA; p = 0.0005; n = 6 for acidified milk, milk ST5 
+ R0175 and milk ST5 + R0052, n = 3 for milk unfermented, challenged cell 
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Figure 17: Viability of non-differentiated U937 monocytic cells (5 × 105 cells/mL) 
following concurrent incubation with soy ferments and soy controls (1/100 in 
RPMI 1640) and 20 ng/mL TNF-α for 24 hours.  Data shown as mean percent 
viability ± SEM.  (One-way ANOVA; p = 0.3304; n = 6 for acidified soy, soy ST5 + 
R0175 and soy ST5 + R0052, n = 3 for soy unfermented, challenged cell control 
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Figure 18: Viability of ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) following concurrent incubation with milk ferments and milk controls 
(1/100 in RPMI 1640) and 20 ng/mL TNF-α for 24 hours. Data shown as mean 
percent viability ± SEM.  (One-way ANOVA; p = 0.1290; n = 6). Pre-treatment 
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Figure 19: Viability of ATRA-differentiated U937s (5 × 105 cells/mL) following 
concurrent incubation with soy ferments and soy controls (1/100 in RPMI 1640) 
and 20 ng/mL TNF-α for 24 hours.  Data shown as mean percent viability ± SEM.  
(One-way ANOVA; p = 0.0092; n = 6; multiple comparisons test did not indicate 
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Figure 20:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD54 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA, p = 0.0055,        
n = 3).  Pre-treatment MFI was 1119.1 ± and 435.3 and unchallenged MFI was 
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Figure 21:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD54 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA, p = 0.0406,        
n = 3).  Pre-treatment MFI was 1119.1 ± and 435.3 and unchallenged cell control 
MFI was 725.1 ± 109.4.  Dunnett’s post test used (* shows significant difference 
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Figure 22:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD58 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA, p = 0.0020,        
n = 3).  Pre-treatment MFI was 585.9 ± and 230.2 and unchallenged cell control 
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Figure 23:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD58 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA, p = 0.0644,        
n = 4).  Pre-treatment MFI was 585.9 ± and 230.2 and unchallenged cell control 





CD54 Expression of TNF-α Challenged ATRA-Differentiated U937


































































Figure 24:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD54 expression by ATRA-differentiated U937 macrophage-like cells 
(5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA,    
p = 0.0298, n = 5 for challenged cell control, n = 4 for milk controls and ferments).  
Pre-treatment MFI was 639.2 ± 304.8 and unchallenged cell control MFI was 
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Figure 25:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD54 expression by ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA, p = 0.0012, n = 5 
for challenged cell control, n = 4 for soy controls and ferments).  Pre-treatment 
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Figure 26:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD58 expression by ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA, p = 0.0218, n = 5 
for challenged cell control, n = 4 for soy controls and ferments).  Pre-treatment 
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Figure 27:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD58 expression by ATRA-differentiated U937 macrophage-like cells 
(5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours.  Data shown as mean MFI ± SEM (One-way ANOVA,    
p = 0.0788, n = 5 for challenged cell control, n = 4 for milk controls and ferments).  
Pre-treatment MFI was 654.9 ± 52.4 and unchallenged cell control MFI was 
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Figure 28:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD80 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured bars represent 
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Figure 29:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD80 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured bars represent 
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Figure 30:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD80 expression by ATRA-differentiated U937 macrophage-like cells 
(5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured 
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Figure 31:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD80 expression by ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured bars represent 
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Figure 32:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD86 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured bars represent 
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Figure 33:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD86 expression by non-differentiated U937 monocytic cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured bars represent 
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Figure 34:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD86 expression by ATRA-differentiated U937 macrophage-like cells 
(5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured 
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Figure 35:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD86 expression by ATRA-differentiated U937 macrophage-like cells (5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours.  Data shown as mean MFI ± SEM.  (n = 3).  Coloured bars represent 
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Figure 36:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on IL-8 production by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean concentration in pg/mL 
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Figure 37:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on IL-8 production by ATRA-differentiated U937 macrophage-like cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean concentration in pg/mL 
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Figure 38:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on IL-8 production by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean concentration in pg/mL 
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Figure 39:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on IL-8 production by ATRA-differentiated U937 macrophage-like cells (2.5 
× 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours in simulated microgravity.  Data shown as mean 
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Figure 40:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on TGF-β1 production by non-differentiated U937 monocytic cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 48 hours in simulated microgravity.  Data shown as mean concentration in 







Total TGF-β1 Production by TNF- α Challenged ATRA-Differentiated 
U937 Macrophage-Like Cells Concurrently Treated with Milk 




























































Figure 41:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on TGF-β1 production by ATRA-differentiated U937 macrophage-like cells 
(2.5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 48 hours in simulated microgravity.  Data shown as mean 
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Figure 42:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on TGF-β1 production by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
48 hours in simulated microgravity.  Data shown as mean concentration in pg/mL 
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Figure 43:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on TGF-β1 production by ATRA-differentiated U937 macrophage-like cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 48 hours in simulated microgravity.  Data shown as mean concentration in 
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Figure 44: Viability of non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) following concurrent incubation with soy ferments and soy controls 
(1/100 in RPMI 1640) and 20 ng/mL TNF-α for 24 hours.  Data shown as mean 
percent viability ± SEM.  (One-way ANOVA; p = 0.8655; n = 3). Pre-treatment 
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Figure 45: Viability of ATRA-differentiated U937 macrophage-like cells (2.5 × 105 
cells/mL) following concurrent incubation with soy ferments and soy controls 
(1/100 in RPMI 1640) and 20 ng/mL TNF-α for 24 hours.  Data shown as mean 
percent viability ± SEM.  (One-way ANOVA; p = 0.6890; n = 3). Pre-treatment 
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Figure 46: Viability of ATRA-differentiated U937 macrophage-like cells (2.5 × 105 
cells/mL) following concurrent incubation with milk ferments and milk controls 
(1/100 in RPMI 1640) and 20 ng/mL TNF-α for 24 hours.  Data shown as mean 
percent viability ± SEM.  (One-way ANOVA; p = 0.0302; n = 4). Pre-treatment 
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Figure 47: Viability of non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) following concurrent incubation with milk ferments and milk controls 
(1/100 in RPMI 1640) and 20 ng/mL TNF-α for 24 hours.  Data shown as mean 
percent viability ± SEM.  (One-way ANOVA; p = 0.0447; n = 3). Pre-treatment 
viability was 87.7 ± 5.2 %.  Dunnett’s post test used (* shows significant 
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Figure 48:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD54 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-way 
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Figure 49:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD54 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-way 
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Figure 50:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD54 expression by ATRA-differentiated U937 macrophage-like cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-
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Figure 51: Effect of milk ferments and milk controls (1/100 dilution in RPMI 1640) 
on CD54 expression by ATRA-differentiated U937 macrophage-like cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-
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Figure 52:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD58 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-way 
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Figure 53:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD58 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-way 
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Figure 54:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD58 expression by ATRA-differentiated U937 macrophage-like cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 24 hours in simulated microgravity.  Data shown as mean MFI ± SEM (One-
way ANOVA, p = 0.0430, n = 3).  Pre-treatment MFI was 302.4 ± 143.2.  
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CD58 Expression of TNF-α Challenged ATRA-Differentiated 
U937 Macrophage-Like Cells Concurrently Treated with Milk 


































































Figure 55:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD58 expression by ATRA-differentiated U937 macrophage-like cells 
(2.5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours in simulated microgravity.  Data shown as mean MFI ± 
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Figure 56:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD80 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM.  (n = 3).  
Coloured bars represent CD80 MFI, black bars represent isotype control MFI, 






CD80 Expression of TNF-α Challenged U937 Monocytic Cells 




































































Figure 57:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD80 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM.  (n = 3).  
Coloured bars represent CD80 MFI, black bars represent isotype control MFI, 
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Figure 58:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD80 expression by ATRA-differentiated U937 macrophage-like cells 
(2.5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours in simulated microgravity.  Data shown as mean MFI ± 
SEM.  (n = 3).  Coloured bars represent CD80 MFI, black bars represent isotype 





CD80 Expression of TNF-α Challenged ATRA-Differentiated 
U937 Macrophage-Like Cells Concurrently Treated with Soy 








































































Figure 59:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD80 expression by ATRA-differentiated U937 macrophage-like cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 24 hours in simulated microgravity.  Data shown as mean MFI ± SEM.          
(n = 3).  Coloured bars represent CD80 MFI, black bars represent isotype control 
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Figure 60:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD86 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM.  (n = 3).  
Coloured bars represent CD86 MFI, black bars represent isotype control MFI, 
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Figure 61:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD86 expression by non-differentiated U937 monocytic cells (2.5 × 105 
cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation for 
24 hours in simulated microgravity.  Data shown as mean MFI ± SEM.  (n = 3).  
Coloured bars represent CD86 MFI, black bars represent isotype control MFI, 
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Figure 62:  Effect of soy ferments and soy controls (1/100 dilution in RPMI 1640) 
on CD86 expression by ATRA-differentiated U937 macrophage-like cells (2.5 × 
105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent incubation 
for 24 hours in simulated microgravity.  Data shown as mean MFI ± SEM.  (One-
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Figure 63:  Effect of milk ferments and milk controls (1/100 dilution in RPMI 
1640) on CD86 expression by ATRA-differentiated U937 macrophage-like cells 
(2.5 × 105 cells/mL) in the presence of 20 ng/mL TNF-α following concurrent 
incubation for 24 hours in simulated microgravity.  Data shown as mean MFI ± 










   
Generally, due to the need for astronauts to rebuild and maintain their 
immunity while in a mission, a probiotic soy or milk based ferment which 
decreases pro-inflammatory responses and/or increases anti-inflammatory 
responses would be of benefit.  For example, IL-1, a pro-inflammatory cytokine, 
has been reported to be increased in astronauts during space flight (Huntoon et 
al, 1994; Stein et al, 1993; Leach et al, 1988; Leach et al, 1983).  Such a product 
could also provide nutritional benefits such as calcium, B vitamins and 
antioxidants, which may help to address other health issues encountered in long-
term space flight.  With health risks such as bone loss, body fluid regulation, 
issues with the cardiovascular system and nutritional deficiencies due to a 
relatively small variety of food items available to astronauts (Heer et al, 2000), it 
is important to consider ways to supply nutrients to avoid or inhibit these issues.  
Lane et al (1998) has already noted that astronauts vary their nutritional intake 
while in flight compared to pre-flight, and that physiological changes due to 
dietary disruption can ultimately affect the immune system (Field et al, 2002; 
Sonnenfeld, 2001; Sonnenfeld, 1998).  
The role of the GI tract microbiota in maintaining host health has recently 
been emphasized by numerous studies showing effects on the immune system 
(Clarke et al, 2010; Neish, 2004).  In addition to effects on metabolism 
(Turnbaugh et al, 2009; Wikoff et al, 2009) and even behavior (Collins and 
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Bercik, 2009), it has been suggested that a key role of the gut microbiota is to 
maintain a homeostatic effect at the gut mucosa and prevent excessive          
pro-inflammatory responses that would otherwise result from the constant 
contact with antigenic, dietary and microbial stimuli.  Disruptions in the astronaut 
microbiota could potentially result in a loss of this homeostatic effect (Hales et al, 
2002).  The ferments tested in this study could have the ability to regulate innate 
mucosal immune responses and possibly “restore the balance”.  While the 
effects of these ferments suggest anti-inflammatory activity, it is important to note 
that this is not equivalent to immunosuppression, and it would be anticipated that 
the astronauts’ immune system would still able to ward off typical infections. 
The LAB strains used for ferment preparation were selected for this 
research because they have previously shown the potential to modulate the 
immune system (Wood et al, 2007; Wallace et al, 2003; Easo et al, 2002), 
prevent infection (Johnson-Henry et al, 2005; Johnson-Henry et al, 2004), reduce 
symptoms of stress (Gareau et al, 2007; Zareie et al, 2006) and produce 
bioactive compounds (Fiander et al, 2005).  Clinical trials have also been 
completed using these strains to reduce symptoms of inflammation in the gut 
(Benes et al, 2006; Haskey and Dahl, 2006; Kocián, 2004).  Champagne et al 
(2009) screened potential strains for their ability to grow in both MB and SB.  
Unfortunately, at that point, one of the more effective strains, Lactobacillus 
rhamnosus R0011 was excluded because it did not efficiently grow in SB.  Initial 
screening of pure (one probiotic strain alone per ferment) and mixed cultures     
(a starter culture plus one probiotic strain per ferment) was completed by Wagar 
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et al (2009) on HT-29 IECs and it was determined that mixed cultures were more 
effective than pure cultures. 
The probiotic milk and soy ferments discussed herein have demonstrated 
the ability to modulate certain aspects of the innate immune system, both in 
normal gravity and in simulated microgravity.  These ferments affected the U937 
cells differently depending on the cellular differentiation stage (monocyte or 
macrophage) and whether or not the cells were in simulated microgravity.  While 
these results are based on an in vitro monocyte/macrophage system, such an 
approach provides a useful initial step in testing for immunomodulatory activity, 
and determining which ferments, conditions and immune parameters warrant 
further testing, and may provide guidelines to potential in vivo administration.   
The differences in TGF-β1 secretion between non-differentiated and 
ATRA-differentiated U937s in normal gravity (Figure 11) demonstrate why it was 
necessary to look at more than one cellular differentiation stage.  This supports 
the initial hypothesis that soy and milk ferments would affect the two 
differentiation stages differently, and, on a broader scale, two related cell types 
(monocytes and macrophages).  The same pro-inflammatory cytokine (TNF-α) 
can act differently depending on its target cells and their state.  This was also 
reflected in the differences seen in CD58 expression: TNF-α challenged non-
differentiated U937s (monocyte stage) express more CD58 than TNF-α 
challenged ATRA-differentiated U937s (macrophage stage) by about 150 mean 
fluorescence intensity (MFI).  CD86 expression by TNF-α challenged non-
differentiated U937s was about 36 MFI while expression by TNF-α challenged 
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ATRA-differentiated U937s was about 190 MFI.  Even though these two 
differentiation stages arose from the same cell type, it is apparent that they act 
dissimilarly in their response to a pro-inflammatory challenge.   
Aside from differences in effects of unchallenged and challenged cell 
controls, the ferments themselves act differently on non-differentiated and ATRA-
differentiated U937s with respect to effects on cytokine production.  Milk controls 
and ferments did not affect IL-8 production by non-differentiated U937s (Figure 7) 
but soy fermented with ST5 + R0175 did (Figure 8).  Milk and soy controls greatly 
increased IL-8 production by ATRA-differentiated U937s (Figure 9 and 10) 
compared to non-differentiated U937s:  mean IL-8 production was approximately 
1800 pg/mL (both milk controls) for non-differentiated U937s versus 20000 
pg/mL (unfermented milk treated) and 330000 pg/mL (acidified milk treated) by 
ATRA-differentiated U937s, producing a greater than 11 and 18 fold increase, 
respectively.   Milk ferments and controls all significantly reduced TGF-β1 
production by non-differentiated U937s (Figure 12) but soy ferments and controls 
did not (Figure 13).  However, differentiated U937s secreted IL-8 similarly in 
response to treatment with controls and ferments regardless of ferment base (MB 
or SB) (Figure 9 and 10).   Effects on cell surface molecules CD54, CD58 and 
CD86 expression showed similar patterns regardless of ferment base (Figure 20 
to 27, 32 to 35) .  This suggests the possibility that the cytokines used in this 
study (in contrast to cell surface molecules) may be influenced by by-product(s) 
generated by the probiotic bacteria that is determined by the base in which they 
are fermented (for example, product X is produced while fermenting in milk, but 
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product Y is produced while fermenting in soy).  The presence of isoflavones in 
soy milk gives the probiotic bacteria a unique substrate for fermentation (Yeo and 
Liong, 2010; Marazza et al, 2009; Pham and Shah, 2009; Chun et al, 2008; 
Rekha and Vijayalakshmi, 2008) compared to dairy milk, which does not contain 
isoflavones but does contain other structurally similar animal-derived estrogen-
like hormones.  Examples of soy isoflavones include genistein and daidzein, 
which have been shown to be potent inhibitors of leukocyte activity including 
cytokine secretion (Sakai and Kogiso, 2008; Gredel et al, 2008).  These effects 
are possibly mediated through suppression of NF-κB, although this effect has 
been reported to be independent of estrogenic activity (Vanden Berghe et al, 
2006), suggesting other components of soy may also be responsible for 
bioactivity.  Estrogen has been shown to play a regulatory role in T-cell 
dependent immune responses by inducing rapid signaling events (Adori et al, 
2010). 
Differences in responses between non-differentiated U937s and ATRA-
differentiated U937s may be due to changes in cell surface receptors induced 
during differentiation.  Aside from an increased expression of CD11b, other cell 
surface receptors may be up- or down-regulated in leukocytes treated with ATRA 
(Ozpolat et al, 2007; Rizzi et al, 2007; Xia et al, 2006; Li et al, 2003) such as 
CD52, Bfl-1/A1, programmed cell death-4 and death-associated protein kinase 2.  
With different receptors able to bind to possible ligands in fermented soy and 
milk, pathways may be activated that were quiescent in non-differentiated cells.  
Estrogen receptors may be upregulated, in which case isoflavones and their 
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metabolites found in SB might be increasing the response of differentiated U937s 
treated with soy controls and ferments.  In differentiated cells treated with milk 
controls and ferments (Figure 9 and 10), it is possible that responses could be 
due to an increase in EGF and IGF receptors.  EGF and IFG found in cow’s milk 
(Purup et al, 2006; Herbst, 2004; Forsyth 1996; Glimm et al, 1992) are able to 
bind to their human receptors.  If EGF Receptor (EGFR) and IGF Receptors 1 
and 2 (IGF1R and IGF2R) that may have been upregulated during ATRA-
mediated cellular differentiation, increased responsiveness of differentiated U937 
cells would be anticipated, and this would be an interesting topic for further study.  
EGFR activates down-stream several signal-transduction cascades such as 
MAPK/ERK leading to DNA synthesis and cell proliferation (Oda et al, 2005) and 
leads to increased IL-6 concentrations in asthma models (Tsuchiya et al, 2010) 
and increased IL-8 in skin injury (Büchau, 2010).  IGF receptors seem a less 
likely player in effects on monocytes and macrophages as most literature focuses 
on their role in T-cell activation (Baudler et al, 2005; Sharp et al, 2005; Stentz 
and Kitabchi, 2003).    
Another factor in milk which may be causing this increase in IL-8 in 
differentiated U937s is lactoferrin (LF) which has antimicrobial activity and is part 
of mucosal innate defenses (Sánchez et al, 1992).  Bournazou et al (2010) has 
described inhibition of eosinophil migration by LF regardless of source (milk or 
cell derived).  LF has also been described to modulate APC migration, 
expression of cytokines, chemokines and other effector molecules (Puddu et al, 
2009).  LF concentrations can be found in increased concentrations locally in 
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areas of Inflammatory Bowel Syndrome (Uchida et al, 1994) and allergic 
inflammation (van de Graaf et al, 1991).  Fermentation by R0175 and R0052 may 
be disrupting this normal pattern by modifying the LF content in milk itself or 
influencing its activity, or the effects of R0175 and R0052 themselves may cancel 
out any negative effects of LF.  Milk estrogen acting through EGF receptors, if 
up-regulated, and LF provides possible candidates for the increased pro-
inflammatory response to unfermented and acidified milk controls (Figure 9 and 
10). 
Referring to acidified controls specifically, differentiated U937s reacted 
differently, with respect to cytokine production, than non-differentiated U937s.  
SCFA have recently been implicated in effects on NF-kB expression induced by 
lactic acid bacteria (Kumar et al, 2009) and so lactic acid milk and soy controls 
were used throughout this study.  Lactic-acid acidified soy and milk controls were 
generally not as effective at decreasing IL-8 (Figure 9, 10, 37 and 39) and     
TGF-β1 (Figure 14, 15, 41 and 43) production in differentiated U937s, suggesting 
SCFA are not as, or at all, effective in the macrophage stage, in normal gravity 
and simulated microgravity.  In fact, Bailón et al (2010) suggest that 
macrophages treated with the SCFA butyrate produce inflammatory cytokines.  
Cell surface molecules, if significantly different in response to ferment treatments, 
were typically down-regulated equally by both unfermented and acidified 
controls, regardless of cell differentiation stage, suggesting that SCFA are not 
involved in effects on cell surface molecule expression 
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U937 viability was typically not affected by controls or ferments, except for 
milk fermented with ST5 + R0052, which decreased cell viability in both normal 
gravity and simulated microgravity conditions for non-differentiated U937s 
(Figure 16 and 47), and milk fermented with ST5 + R0175 in simulated 
microgravity conditions for ATRA-differentiated U937s (Figure 46).  This again 
supports the idea that a ferment base-dependent by-product(s) is produced 
during fermentation, which in this case induces apoptosis.  Although there is 
significant cell death, there may be enough viable cells left to produce the 
observed amounts of cytokines. 
The decrease in CD54 expression seen on non-differentiated U937s and 
differentiated U937s in soy and milk controls and ferments and, in both normal 
gravity (Figure 20, 21, 24, 25) and simulated microgravity (Figure 48, 49, 50 and 
51) may prevent both monocyte stage and macrophage stage cells from 
adhering efficiently to endothelial cells (Maio and Del Vecchio, 1992), impeding 
cell travel to the site of infection and therefore limiting the pro-inflammatory 
response.  For soy treated cells, the soy isoflavone genistein may play a role in 
inhibiting monocyte adhesion (Nagarajan et al, 2006) which could explain why 
even unfermented and acidified soy controls down-regulate CD54 expression to 
the same extent as that observed with soy ferments.  Another probiotic strain 
(Enterococcus faecium M-74) administered in an oral capsule was reported in 
Hlivak et al (2005) to decrease CD54 expression on peripheral blood monocytes.  
Roessler et al (2008) also describes two probiotic strains (Lactobacillus 
paracasei Lpc-37 and Bifidobacterium lactis 420) in a fermented milk drink that 
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also significantly decreased CD54 expression.  These effects are similar to what 
was seen in this research with R0175 and R0052.  The fact that this outcome is 
retained in simulated microgravity suggests potential for the use of these 
ferments for astronauts in flight.   
CD58 down-regulation was also consistent in response to treatment with 
milk and soy ferments, on either non-differentiated or differentiated U937s, and in 
normal gravity (Figure 22, 23, 26 and 27) and simulated microgravity (Figure 52, 
53, 54 and 55) conditions.  With less CD58 expressed on the cell surface, 
adhesion between APCs, such as monocytes and macrophages, and T-cells is 
weakened.  At time of writing, there is no literature linking the possible effects of 
probiotics or ferments to CD58 expression, so this is a novel finding.   However, it 
would appear that strains R0175 and/or R0052 might use a common mechanism 
for this down-regulatory effect, as regardless of ferment base, these strains have 
down-regulated CD58. Up-regulation of CD58 expression by TNF-α challenged 
non-differentiated and differentiated U937s may be a response unique to 
leukocytes, as Kvale and Brandtzaeg (1993) report no up-regulation of CD58 on 
two hepatocytic cell lines (Hep-G2 and SK-Hep-1) after stimulation with TNF-α, 
and Kvale et al (1992) also report no up-regulation in human IECs of CD58 by 
response to TNF-α.  After an antigen/MHC provides the first signal to a T-cell, a 
secondary signal is provided by interaction between CD2 (LFA-2) on the T-cells 
and CD58 from an APC (Wang et al, 1999; Wingren et al, 1995).   Blocking these 
molecules inhibits this interaction (Crosby et al, 2004), and one can speculate 
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that even reducing their interaction may help regulate T-cell priming during a pro-
inflammatory infection during space travel or otherwise. 
Prior to challenging with TNF-α, non-differentiated and differentiated 
U937s did not express (or expressed very little) CD80 (Figure 28 to 31, 56 to 59) 
or CD86 (Figure 32 to 35, 60 to 63).  This may be a feature unique to the U937 
cell line as several recent papers report constitutive CD80/CD86 expression on 
other monocytes or monocyte-derivatives (Caicedo et al, 2010; Jin et al, 2010; 
Almerighi et al, 2009; Seipel et al, 2009; Cacere et al, 2008), particularly the 
THP-1 monocytic cell line or primary monocytes.  Without CD80/CD86 
expression, T-cells may not be primed efficiently.  TNF-α did not induce 
expression of CD80 by either U937 differentiation stage, but CD86 expression 
was induced in response to TNF-α treatment, with the highest levels being seen 
on differentiated U937s.  No ferment or control treatment increased expression of 
these surface molecules by TNF-α challenged U937s.  Instead, CD86 expression 
appeared slightly lower on TNF-α challenged differentiated U937s treated with 
milk and soy ferments and acidified controls, although further testing would be 
required to verify this effect.  In vivo, deletion or blockade of CD80/86 improves 
survival and attenuates pro-inflammatory cytokine production during microbial 
sepsis in rats (Nolan et al, 2008), illustrating the role these cell surface molecules 
play in pro-inflammatory activity, in addition to their co-stimulatory role in T cell 
activation.   Thus interpreting the biological significance of potential effects on 
CD80/CD86 expression would depend on the context in which expression was 
occurring.   
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In summary, the effects of milk and soy ferments on non-differentiated or 
differentiated U937s varied if the cells were in a normal gravity or simulated 
microgravity situation.  Fermented milk decreased IL-8 production in non-
differentiated U937s in simulated microgravity but not in normal gravity.  Soy had 
the opposite effect on non-differentiated U937s: soy ferments decreased IL-8 
production in normal gravity but not in simulated microgravity.  Effects of 
ferments on TGFβ1 production were opposite to those observed on IL-8 
production.  In non-differentiated U937s, milk ferments decreased TGF-β1 
production in normal gravity but soy ferments decreased TGF-β1 production in 
simulated microgravity.  Differentiated U937s responded to milk and soy 
ferments similarly in both normal gravity and simulated microgravity: milk 
ferments decreased IL-8 production, and soy ferments decreased TGF-β1 
production (See Table 5).  This means that, aside from non-differentiated U937 
cytokine secretion, microgravity did not change effects of the ferments. The 
activity of the probiotics was retained in simulated microgravity. 
Work in Progress and Future Directions 
 
 The work contained in this thesis could branch off into several endeavors.  
The first and maybe most important would be to build on the work of Wagar et al 
(2009) and use the HT-29 IEC line in the HARV to test the effects of these 
ferments on IECs in simulated microgravity.  Since IECs are another important 
player of innate immunity, providing both a physical and immunological barrier in 
the GI tract, this would be an important compliment to this work.  Combined with 
122 
 
the data from this thesis, a greater picture of how these ferments modulate innate 
immunity would be revealed. 
 With respect to monocytes and macrophages, other challenges such as 
IFN-γ, LPS, and IL-1 could be used to determine which cellular signal 
transduction pathway these ferments have an effect on and to better characterize 
the range of immunomodulatory activity they may have.  The JAK-STAT 
pathway, the CD14/TLR4/MyD88/NF-κB pathway and the IL-1R pathway, 
respectively, would potentially be influenced in response to ferment treatment. 
 Although still ongoing at the time of writing, Western blots have revealed 
down-regulation of NF-κB activation induced by TNF-α challenge of non-
differentiated U937s. This down-regulation was observed following pre-
incubation (for 20 hours) with a 1/50 dilution of soy and milk ferments (in RPMI), 
but was not seen for cells pre-incubated with soy or milk controls or RPMI 
controls (personal communication, N. Treiselmann).  Further elucidation of the 
kinetics and dynamics of effects on NF-κB activation will assist the current 
understanding of cellular responses to these ferments, and help to place these 
findings into the context of inflammatory, autoimmune and pathogenic 
challenges, where NF-κB activation is involved. 
 Using a filter to remove the probiotic bacteria from these ferments would 
enable us to discern if the observed effects are dependent on direct bacterial 
contact with the U937s cells, or are due to soluble factors secreted by the 
bacteria or produced from the soy and milk substrates during fermentation.  
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Earlier work from our laboratory with these strains suggested that soluble 
components produced by R0052 and Lactobacillus rhamnosus strain R0011 in 
milk ferments are involved in down-regulating IL-1β-induced prostaglandin E2 
production by HT-29 IEC (Fiander et al, 2005).  Other recent studies have shown 
that indeed secreted factors can contribute to down-regulation of pro-
inflammation based on testing of probiotic-conditioned media (Bayoumi and 
Griffiths, 2010; Heuvelin et al, 2010; Jones and Versalovic, 2009; Broekaert et al, 
2007; Yan et al, 2007).  Further study would be required to determine whether 
such soluble factors are responsible for the effects observed in this study, or 
whether direct contact between LAB in the ferments and the 
monocytes/macrophages is required. 
 The large increase in IL-8 in ATRA-differentiated U937s observed in 
response to combined treatment with TNF-α and milk or soy controls in normal 
gravity conditions also requires further investigation.  Using antibodies to either 
block EGF and IGF receptors or to bind to EGF and IGF themselves, we may be 




This work has characterized immunomodulatory effects of two strains of 
LAB, Bifidobacterium longum R0175 and Lactobacillus helveticus R0052, when 
used to prepare soy and dairy milk ferments.  Both strains have the ability to 
down-regulate pro-inflammatory and regulatory cytokines in some aspect or 
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another, depending on the base (soy or milk) in which they were fermented.  
Expression of cell surface molecules CD54, CD58 and CD86 were also down-
regulated compared to a TNF-α challenged cell control.  Decreased cellular 
adhesion could inhibit the pro-inflammatory response.  Experiments in normal 
gravity conditions were replicated in simulated microgravity using HARV cell 
culture vessels, and in most cases, similar effects were observed.  Although the 
underlying mechanisms responsible for the observed effects require more 
investigation and observation, these results provide insight into effects on this 
aspect of innate immunity and may provide guidelines for potential in vivo 
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Cartoon diagram of GALT (gut-associated lymphoid tissue).  Antigens and 
pathogenic bacteria entering the GI tract encounter macrophages (red, MΦ), 
dendritic cells (yellow, DC), B lymphocytes (green, B) and T lymphocytes (purple, 
T) found in the Peyer’s Patch.  Peyer’s Patches contain specialized epithelium 
cells called microfold cells (orange, M) which sample antigens from the lumen to 
APCs such as macrophages.  B and T cells are stimulated, and pass through the 
MLN were the immune response is amplified.  Activated lymphocytes can then 











A 50 mL HARV vessel set up in a cell culture incubator.  Arrows show how the 













Two versions of the STLV cell culture vessel.  A) shows a 250 mL version, B) 

















Three versions of the HARV cell culture vessel.  A) shows a 50 mL reusable 
version, B) shows a 10 mL reusable version and C) shows a 10 mL disposable 

















A Dremel® 4.8V MiniMite Cordless with a custom conical blending attachment, 
used to homogenize ferments. 
 
 
 
